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Abstract 
Nonenzymatic glycation and oxidation of proteins is increased in 
diabetes mellitus due to hyperglycemia and play an important role in the 
pathogenesis of the disease. Glycation primarily occurs at intrachain lysine 
residues of proteins and results in the formation of an early stage stable 
product as Amadori-modified proteins which undergo further irreversible 
chemical reactions to form advanced glycation end products (AGEs) with the 
involvement of free radicals. One of the pathways for formation of AGEs is 
oxidation of Amadori products through reactive oxygen species produced by 
transition metals. The accelerated accumulation of Amadori and AGE 
products in tissues of diabetic patients, particularly with secondary 
complications like nephropathy, retinopathy and atherosclerosis are 
accompanied by increased free radical activity that contributes to the 
biomolecular damage. Oxidative stress and oxidative damage to tissues are 
common end points of chronic diseases such as diabetes. 
In the present study, poly-L-lysine was glycated non-enzymatically by 
incubating with glucose for 7 days. Glycated poly-L-lysine was further 
modified by hydroxyl radical (OH), the most reactive of the reactive oxygen 
species (ROS), generated by Fenton reaction. The modified poly-L-lysine 
showed conformational and structural changes on analysis by various 
colorimetric, spectral and immunological studies. The studies reveal 
remarkable changes in poly-L-lysine upon glycation and oxidation. 
The colorimetric NBT assay showed significantly high yield of early 
glycation (Amadori) products in the glycated poly-L-lysine which was 
confirmed by increased yield of 5-hydroxymethylfurfuraI (HMF) from 
Amadori products of glycated poly-L-lysine. ROS-glycated poly-L-lysine 
showed low levels of Amadori products and HMF while a negligible content 
was found in native poly-L-lysine. The same samples of modified poly-L-
lysine were used for further studies. 
Studies with specific and non-specific antioxidants and metal chelator 
on ROS-glycated poly-L-lysine showed inhibition of the ROS modification. 
The significant inhibition observed with EDTA, catalase and mannitol showed 
a definite role of hydroxyl radical, produced by Fenton reaction, in the ROS 
modification of glycated poly-L-lysine and AGE formation. 
Glycated and ROS-glycated poly-L-lysine exhibited hyperchromjcity 
as compared to unmodified poly-L-lysine in the far-UV spectra. These 
changes are indicative of structural perturbation in poly-L-lysine on 
modifications. Far-UV c.d. spectra of modified poly-L-lysine showed 
significant decrease in molar ellipticity together with a change in c.d. signal 
of modified poly-L-lysine as compared to native poly-L-lysine. The results 
reiterate the earlier observation of structural perturbation in modified poly-L-
lysine due to alterations in mean residue weight and conformational changes 
induced by the modification. 
The fluorescence studies exhibited reduced fluorescence intensity in 
the case of modified poly-L-lysine as compared to the native form. The 
fluorescence intensity of ROS-glycated poly-L-lysine was even less. The 
decrease in intensities of modified poly-L-lysine is due to loss of 
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intramolecular interactions between lysine side chains, a phenomenon 
responsible for the observed fluorescence of unmodified poly-L-lysine. 
The studies on FT-IR and ' H - N M R spectra of modified poly-L-lysine 
showed characteristic bands and signals corresponding to chemical groups of 
Amadori products and N'^-carboxymethyllysine (CML), an advanced glycation 
endproduct as well as shift in bands and signals assigned for other chemical 
groups present in the native poly-L-lysine. These results confirmed the 
presence of Amadori products and CML in glycated and ROS-glycated poly-
L-lysine respectively. 
Native and both the modified samples of poly-L-lysine were used to 
induce antibodies in rabbits. Modified poly-L-lysine was found to be 
antigenic, producing high titre antibodies. The antigenic specificity of the 
induced antibodies was studied by direct binding ELISA, competition ELISA 
and band shift assay. The antigens exhibited a high degree of specificity for 
the induced antibodies. Anti-glycated and anti-ROS-glycated poly-L-lysine 
antibodies showed preferential recognition of glycated and ROS-glycated 
poly-L-lysine in a competition assay. Anti-glycated poly-L-lysine antibodies 
recognized Amadori specific epitopes present in glycated poly-L-lysine. The 
induced antibodies showed polyspecificity as they recognized other similarly 
modified lysine rich proteins, pointing towards generation of common 
epitopes in the modified lysine residues. 
Sera of diabetes patients were probed for the presence of antibodies 
reactive with native, glycated, ROS-glycated and NaBH4 reduced glycated 
forms of poly-L-lysine. Direct binding ELISA showed greater recognition of 
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the modified forms of poly-L-lysine samples as compared to the native form. 
Specific binding was ascertained by competition ELISA. Moreover, 
significantly higher recognition of Amadori-rich glycated poly-L-lysine over 
other modified forms of poly-L-lysine was observed in the sera of diabetes 
patients with and without secondary complications like nephropathy, 
retinopathy and atherosclerosis. The higher binding to glycated and ROS-
glycated forms of poly-L-lysine over native poly-L-lysine of serum antibodies 
in diabetes patients suggests the involvement of modified poly-L-lysine in the 
production of autoantibodies in these patients. The antigenic epitope 
specificity of antibodies induced in rabbits and of the antibodies present in 
the sera of diabetes patients towards Amadori-rich glycated poly-L-lysine was 
confirmed by binding assay with NaBH4 reduced glycated poly-L-lysine. Both 
the antibodies exhibited reduced binding to the NaBH4 reduced poly-L-lysine 
thereby confirming the specific recognition of the Amadori product. 
Human IgG is known to be rich in lysine residues. Glycation and ROS 
damage in the IgG from diabetes patients were detected using anti-glycated-
and anti-ROS-glycated- poly-L-Iysine antibodies as probes. IgG from 
different diabetic patients inhibited antibodies binding to their respective 
antigens demonstrating the presence of Amadori and AGE specific epitopes 
on IgG. The study is in conformity with the earlier reports that glycation and 
giycoxidation causes in vivo protein modifications. Glycation and oxidative 
damage in the diabetes IgG was further confirmed by a high degree of binding 
of the induced anti-glycated poly-L-lysine and anti-ROS-glycated poly-L-
lysine antibodies to the in vitro glycated and ROS modified IgG from healthy 
subjects. 
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In conclusion, glycation and ROS modification of poly-L-Iysine render 
it higtily immunogenic generating antigen specific polyclonal antibodies. The 
modified poly-L-lysine (i.e. glycated and ROS-glycated forms) are 
representative models of the in vivo glycated and ROS-glycated damage of 
lysine residues of proteins resulting in autoantibodies induction in diabetes 
patients. Recognition of modified poly-L-lysine samples by serum antibodies 
from diabetes patients strongly points towards the involvement of glycated 
and oxidatively modified lysine rich proteins in the induction of 
autoantibodies in these patients. Amadori products, present as cyclic forms in 
the glycated poly-L-lysine, are the potential recognition epitopes of anti-
glycated poly-L-lysine antibodies. The induced anti-glycated poly-L-lysine 
and anti-ROS-glycated poly-L-lysine antibodies detected early and advanced 
glycation mediated damage to the IgG of diabetes patients. It is, therefore, 
suggested that glycation and ROS modification of lysine rich proteins appears 
to play a major role in the production of autoantibodies in diabetes mellitus 
and in associated complications of the disease. 
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Introduction 
Proteins are the most important of the macromolecules of living substances. 
They are built up from a section of 20 different amino acids joined or linked by 
peptide bonds. Out of these 20 amino acids, 8 are essential amino acids. The product 
formed by a peptide bond between two amino acids is a dipeptide. The peptides 
containing 2-10 repeating amino acid residues (-NH-CH-CO) are referred to as 
oligopeptide. A polypeptide is formed by more than 10 amino acid residues while a 
protein has more than 100 residues. The proteins are thus polymers produced by 
linking together of a number of similar small units. 
Poly-L-lysine 
Poly-L-lysine is a homopolymer, consisting of many intrachain lysine residues 
and a large number of free e-amino groups. Lysine is a base and an essential amino 
acid that the body needs for growth and tissue repair. It cannot be synthesized in the 
body and its breakdown is irreversible. It plays an essential role in the production of 
carnitine, a nutrient responsible for converting fatty acids into energy and helping to 
lower cholesterol. Lysine appears to help the body absorb and conserve calcium and it 
plays an important role in the formation of collagen. A unique property that lysine has 
is that it does not change its nitrogen with other circulating amino acids. O-
Glycosylation of lysine residues in the endoplasmic reticulum or golgi apparatus is 
used to mark certain proteins for secretion from the cell. Lysine is involved in the 
browning reaction, or carmelization, in foods such as pastries, doughnuts, cookies and 
cereals. In this process, lysine and sugar become linked together in a way that makes 
lysine difficult for the body to absorb. It has been suggested that lysine may be 
beneficial for those with herpes simplex infections (Griffith et al, 1978). However, 
more research is needed to fully substantiate this claim. Lysine can help to alleviate 
the symptoms of coldsores. They help to speed up the healing process if taken 
immediately. 
Antigenicity of poly-L-lysine 
Polypeptides of single amino acids with absence of aromatic groups such as 
poly-L-lysine are not antigenic in any species of animals even though they may have 
molecular weight over 50 KD (Rao, 1972; Goldsby et al, 2003) However, polylysine 
with only 7 or 8 units to which is attached a single dinitrophenyl group is im-
1 
munogenic in guinea-pigs giving rise to both antibody production as well as cellular 
immunity as indicated by the delayed skin sensitization to the polypeptide (Green et 
al, 1966; Stupp et al, 1971; Rao, 1972). The immunogenicity depends also on the 
species and the strain of the animal used. Some strains of animals responded to 
particular structure and other strains did not respond. For example, strain 2 of guinea-
pigs produced antibodies when immunized with dinitrophenyl poly-L-lysine (DNP-
PLL) while strain 13 did not produce any antibody. Breeding experiments showed 
that response to DNP-PLL is due to the so called poly-L-lysine gene which is present 
in strain 2 and not in strain 13. Cross breeding experiments showed that this gene is 
autosomal and dominant (Levine, 1969; Stupp, 1971). 
Non-enzymatic glycation of proteins/peptides 
Non-enzymatic glycation is initiated by a nucleophilic addition reaction 
between a free amino group of a protein and a carbonyl group from a reducing sugar 
to form a freely reversible Schiff base. This reaction occurs over a period of hours and 
once formed, the labile Schiff base rearranges to a more stable ketoamine 
(fructosamine) or Amadori product (Horvat and Jakas, 2004; LapoUa et al.,, 2005) 
which occurs as cyclic forms in equilibrium for added stability (Armbruster, 1987; 
Yaylayan and Huyghues-Despointes, 1994) (Fig. 1). It is a classical covalent reaction 
in which, by means of N-glycoside bonding, the sugar-protein complex is formed 
through a series of chemical reactions described by a chemist, Maillard (Singh et al, 
2001). 
Amadori-modified proteins as an early stage Maillard reaction product 
undergo further reactions, involving dicarbonyl intermediates, such as 3-
deoxyglucosones (3-DG), giving rise to advanced glycation end products (AGEs) 
which are also formed through other described pathways (Turk, 2001; Thomalley et 
al, 2003) (Fig. 2). It was believed that the primary role in Maillard reactions was 
exclusively played by high glucose concentration. However, in spite of the fact that 
sugars are the main precursors of AGE compounds, numerous intermediate carbonyl 
compounds (glyoxal, methylglyoxal, deoxyglucosones) formed through degradation 
of Amadori products by oxidation and dehydration reactions, again react with the free 
amino groups of proteins and act as propagators of non-enzymatic glycation reactions. 
These compounds are much more reactive than the sugars from which they are 
derived. Such intermediary products are also generated during glycolysis 
(methylglyoxal), lipid peroxidation (Thomalley et al., 2003) or along the polyolic 
pathway (Turk, 2001) and can also be formed by autoxidation of carbohydrates 
(glyoxal) (Thomalley et al, 1999; Cervantes-Laurean et al, 2005). 
Glycation of proteins leads to the formation of reactive intermediates, 
crosslinking of proteins and the formation of brown and fluorescent polymeric 
materials (McRobert et al, 2003; Lapolla et al, 2005). Following reaction is 
described for glucose-dependent cross-linking of protein under physiological 
conditions (Eble et al, 1983): 
GLUCOSE + PROTEIN —> —• GLUCOSE-PROTEIN 
+ —• (PR0TEIN)2 
PROTEIN 
In the recent years extensive investigations have been made on the glycation 
of proteins exposed to high glucose concentrations, e.g. lens crystalline proteins 
(Stevens et al 1978), insulin (Dolhofer and Wieland, 1979), proteins of erythrocyte 
membrane (Miller et al, 1980), bovine serum albumin (Arakawa and Timasheff, 
1982), human serum albumin (Shaklai et al, 1984), enzymes (Coradello et al, 1982), 
high and low-density lipoproteins (Krittein et al, 1990), peripheral nerve myelin 
(Green, 1980), elastin (Baydanoff e/ al, 1994), collagen (Fu et al 1994), IgM and 
IgO (Menini et al, 1993; Newkirk et al, 2003). 
Glycation occurs primarily at intrachain lysine residues of proteins 
(Watkins et al, 1985). It takes place at s-amino groups of lysine or hydroxylysine 
residues as well as at a-amino groups of amino terminal residues. The amino groups 
of arginine residues (Ledl and Schleicher, 1990) and that of histidine, tryptophan and 
cysteine residues (Munch et al, 1999) are also amenable to glycation. The valine 
residues have been identified as highly reactive sites in hemoglobin (Watkins et al, 
1985). Specific lysine residues in hemoglobin and human serum albumin have also 
been identified as preferential sites of glycation in vivo. In hemoglobin, the most 
reactive lysine residues appeared to be located at carboxylate groups in the primary or 
three-dimensional structure of the protein, while in albumin the reactive lysine is 
adjacent to another lysine residue in the primary sequence. 
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Nonenzymatic glycation of proteins, peptides and other macromolecules has 
been implicated in a number of pathologies, most clearly in diabetes meliitus, normal 
aging and neurodegenerative amyloid diseases such as Alzheimer's. Numerous 
studies have advocated a possible link between hyperglycemia/AGEs and the 
pathogenesis of diabetic complications such as retinopathy, nephropathy, neuropathy, 
and vasculopathy (Kimura el ai, 1998). 
Early glycation product 
Measurement of early-stage glycation product (Amadori product) is routinely 
used to evaluate metabolic control in diabetic patients. The two parameters commonly 
used are HbAlc and glycated serum proteins (Ahmed, 2005). HbAlc is derived from 
the non-enzymatic reaction between glucose and the amino groups of valine and 
lysine of P-globin (John, 1997). 
Glycated serum proteins are the products of the non-enzymatic reaction 
between the glucose and the free amino groups of senmi proteins. Measurement of 
early glycation product expresses metabolic control during the last two weeks because 
the half-life of albumin and other serum proteins are close to 15 days (Schwartz, 
1995; Furth, 1997; Goldstein et al, 2004). High level of Amadori products are formed 
through glucose mediated glycation of collagen, HSA and glutathione (Fu et al, 
1994; Nagai et al, 1997; Linetsky et al, 2005). 
Advanced glycation end products (AGEs) 
N^-carboxymethyllysine (CML) and pyralline are non-fluorescent and non-
cross-linking AGEs while pentosidine and crossline are fluorescent and cross-linking 
AGEs (Ahmed, 2005). CML was formed from oxidative degradation of N"-formyl-
N^-fructoselysine (fFL) in glycated protein (Ahmed et al, 1986) or from a reaction of 
glyoxal with proteins (Jakus and Rietbrock, 2004). The browning of fFL incubation 
mixtures proceed to a greater extent under nitrogen than air, suggesting that oxidative 
degradation of Amadori adducts to form CML may have a role in limiting the 
consequences of protein glycation in the body. In air the concentration of the Amadori 
compound is more rapidly decreased by its conversion to CML and EA (erythronic 
acid) which are inert compounds (Ahmed et al, 1986). CML formation was also 
reported from hydroxyl radical mediated modification of Amadori products of 
proteins (Nagai et al, 1997) (Fig. 3). 
Protein modification with AGE is irreversible, as there are no enzymes in the 
body that would be able to hydrolyze AGE compounds. These structures then 
accumulate during the lifespan of the protein on which they have been formed. 
Examples include all types of collagen, albumin, basic myelin protein, eye lens 
proteins, lipoproteins and nucleic acid. The major biological effects of excessive 
glycation include: inhibition of regulatory molecule binding, cross-linking of glycated 
proteins, trapping of soluble proteins by glycated extracellular matrix, decreased 
susceptibility to proteolysis, inactivation of enzymes, abnormalities of nucleic acid 
function and increased immunogenicity in relation to immime complex formation 
(Turk, 2001). 
AGEs generate oxygen free radicals that may potentiate the development of 
atherosclerosis. Thus, AGEs might encourage aggregation of human platelets through 
oxidative stress (Bemheim et ai, 2001). Protein glycation and AGEs are accompanied 
by increased free radical activity that contributes towards the biomolecular damage in 
diabetes. Receptors for AGEs (RAGE) are present on many cell types, particularly 
those affected in diabetes. Studies suggest that interaction of AGEs with RAGE alter 
intracellular signalling, gene expression, release of proinflammatory molecules and 
free radicals that contribute towards the pathology of diabetic complications (Watkins 
et al, 1985). Advanced glycation end products depress superoxide production by 
stimulated polymorphonuclear leukocytes. As superoxide plays an essential role in 
bactericidal activity, this polymorphonuclear leukocyte dysfunction may be a 
contributory factor to the increased prevalence and severity of bacterial infection seen 
in diabetic patients (Neglia et al, 1985). There is evidence of an association of age-
associated diseases with AGEs and free radicals (Stachelin, 1997; Ligier et al., 1998). 
Glycation of poly-L-lysine 
The in vitro exposure of protein to glucose results in the non-enzymatic 
covalent attachment of glucose to lysine side chains in a manner that is observed in 
vivo (Brownlee et al, 1987). This process also occurs in individual with normal 
control of plasma glucose concentrations, but HSA is typically three times 
more glycated than the rest of the population in conditions of hyperglycemia 
(Bourdon et al, 1999) where, during periods of poor control of plasma glucose 
concentration, circulating levels of 25 mM glucose have been recorded. 
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Glycated poly-L-lysine was taken as model compound for non-enzymatic 
glycation on proteins or enzymes. Poly-L-lysine exists as a random coil in solution at 
pH 7.4 and contains only a-amino group and e-amino groups as nonequivalent 
primary amino groups (Neglia et ai, 1985). CML, an advanced glycation endproduct, 
was identified in hydrolysates of poly-L-lysine glycated in phosphate buffer under air 
(Ahmed et al, 1986). A yellow fluorescent compound, 2-(2-Furoyl)-4(5)-(2-furanyl)-
IH-imidazole (FFI) was generated from the acid-hydrolyzed Amadori products of 
poly-L-lysine, which had been incubated for 30 days with excess glucose in 
phosphate buffer, pH 7.5 at 37 °C (Njoroge et al, 1988). 
Free radical generation 
A number of processes in vivo, including the 'respiratory burst' of phagocytic 
cells, metal catalyzed substrate autoxidations, mitochondrial electron transfer and the 
reduction of hydroperoxides generate oxygen free radicals (Halliwell and Gutteridge, 
1984). Free radicals and glycation are central to chronic diseases, degeneration and 
aging. One important source of free radicals is AGEs resulting from non-enzymatic 
glycation and oxidation of proteins and lipids (Thomas et al, 2005). AGEs generated 
oxygen free radicals may potentiate the development of atherosclerosis and might 
encourage aggregation of human platelets through oxidative stress (Hangaishi et al., 
1998). Receptors for AGEs (RAGE) are present on many cell types, particularly those 
affected in diabetes. Studies suggest that interaction of AGEs with RAGE alter 
intracellular signalling, gene expression, release of proinflammatory molecules and 
free radicals that contribute towards the pathology of diabetic complications (Ahmed, 
2005). 
A rise in the oxygen free radical levels has two important effects: damage to 
various cell components and triggering the activation of specific signaling pathways 
NF-KB, ERK, JNK, N A P K , and PKC isoforms (Idris et al, 2001). Reactive oxygen 
species (ROS) generated during various metabolic and biochemical reactions have 
multifunctional effects that include oxidative damage to DNA leading to various 
human degenerative and autoimmune diseases (Hasan et al, 2003), moreover, also 
responsible for the elimination of invading pathogens (Khan et al, 2005). 
ROS encompasses a \mety of diverse chemical species including superoxide 
anions (Oi'"), hydrogen peroxide (H2O2), alkoxyl (RO'), peroxyl (ROO"), hydroxyl 
radicals ("OH), and hydrochlorous acid (HOCl) (Jakus, 2000). ROS are highly 
reactive and have extremely short half-lives. Most estimates suggest that the majority 
of intracellular ROS production is derived from the mitochondria. There are numerous 
mechanisms for generation of ROS in vivo (Emerit et al, 1990). 
Superoxide anion radical 
The superoxide radical is generated within aerobic biological systems during 
both enzymatic and non-enzymatic oxidation. It is eliminated by conversion to H2O2 
and O2 by superoxide dismutase (Fridovich, 1978 and 1986). During glycation, 
Amadori products generate O2* which is converted to H2O2 by non enzymatic 
dismutation reaction (Nagai et al, 1997). The finding that O2" is produced by some 
enzymes and is efficiently scavenged by others (McCord and Fridovich, 1968 and 
1969) led to the view that O2' is an agent of oxygen toxicity. System generating O2' 
has been observed to kill bacteria, inactivate viruses, damage enzymes and membrane 
and destroy animal cell culture (Fridovich, 1978; Halliwell, 1981). 
Hydrogen peroxide and the hydroxyl radical 
Hydrogen peroxide is the second intermediate during the stepwise one-
electron reduction of molecular oxygen. It may however also be generated directiy via 
a two-electron reduction of molecular oxygen. Hydrogen peroxide is a stable 
molecule that is generated as an end product of a variety of oxidation reactions in 
living cells. It may, infact, act as both oxidizing and reducing agents. In presence of 
transition metals, it is thought to give rise to peroxyl radicals and extreme reactive 
hydroxyl radicals via the Fenton reaction (O' Brien, 1969). 
H 2 O 2 + Fe^"/Cu" Fenton reaction ^ pe^VCu^" + ' O H + Of f 
The hydroxyl radicals are a highly reactive oxidizing agent that can react with 
a wide variety of organic molecules. During glycation, "OH generated by Fenton 
reaction between Fe^ "^  and Amadori product-derived endogenous H2O2 plays an 
important role in oxidative cleavage of Amadori compounds into CML (Nagai et al, 
1997). Photolysis by UV irradiation can directly split H2O2 into two 'OH and is 
another important way to produce hydroxyl radical (Masaki et al, 1995). 
H2O2 • •OH + -OH 
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Autoxidation and glycation 
Glucose exists in equilibrium with their enediol, which can undergo 
autoxidation to form an enediol radical. This radical reduces molecular oxygen to 
generate the superoxide radical and becomes oxidized itself to a dicarbonyl 
ketoaldehyde that reacts with protein amino groups forming a ketoamine. Ketoamine 
are similar to, although more reactive, than Amadori products and participate in AGE 
formation (Ahmed, 2005). 
Glycation is a major source of ROS that is generated by oxidative pathways of 
glycation (Rahbar and Figarola, 2003). Several studies support the idea that glycation 
and oxidation are closely linked processes; glucose autoxidation plays an essential 
role in non-enzymatic glycation of protein. In vitro glycated serum albumin showed 
possible interactions between glycation and oxidation (Traverse et al, 1997). 
Contents of the glycated serum albumin are an index of oxidative modification during 
glycation (Fu et al, 1992). In hyperglycemic conditions, most of the carbonyl 
compounds generated by glycation need oxidative steps in their formation. The 
protein dicarbonyl compounds can participate in AGE formation and referred to as 
glycoxidative products (Liggins and Furth, 1997). 
ROS mediated protein oxidation 
The oxidative protein modification by reactive oxygen species leads to a loss 
of physiological function, as in the case of covalent binding of reactive organic 
metabolites to proteins (Bradford and Allen, 1997). Amino acids can undergo 
oxidative damage if they interact with oxygen free radicals. Even peptide bonds are 
subject to oxidative modification by reactive oxygen species. As free radicals are 
capable of initiating chain reactions, cross-linking of soluble and/or membrane bound 
proteins, yield larger aggregates. The direct consequence is a change in higher order 
structure of the protein (e.g., in the quaternary structure), which in turn, results in a 
loss of biological function (Adams et al, 1999; Dhalla et al, 2000; Schoonover, 
2001). Copper bound to biological molecules causes site-specific damage in the 
presence of hydrogen peroxide, and causes greater damage to biological molecules 
than does iron by the formation of hydroxyl radicals (Kocha et al, 1997). 
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The action of autoxidizing sugars on some soluble proteins may mark protein 
for complete intracellular proteolysis. Consequently on free radical generation by 
these sugars, proteins are glycosylated and fragmentation of proteins occur (Wolff and 
Dean, 1987). 
Degradation products of proteins 
Protein damage by radicals is critical in many biological processes. This 
damage may lead to functional inactivation (Willson, 1983), but usually the 
inactivated proteins are degraded, so that proteolysis forms a secondary defence after 
antioxidants. However, when the target proteins are critical for rapid homeostatic 
mechanisms (e.g., transport proteins) or when the proteolytic defense and/or other 
antioxidant defenses are overwhelmed, toxic events may ensue. 
Protein glycation and oxidation are increased in cellular and extracellular 
proteins in diabetes. The physiologically damaged proteins are degraded and replaced 
by the cells (Thomally et al, 2003; Goldberg, 2003). Cellular proteolysis liberates the 
glycated and oxidized amino acids as free adducts. The plasma concentration and 
urinary excretion of the free adducts are increased excessively in Type 1 diabetes 
(Ahmed et al, 2005). 
In the process of glycation, AGE peptides are released as degradation 
products, which partly occur through proteolysis of the matrix component commonly 
named glycotoxins. Glycotoxins (AGE peptides) are very reactive on entering blood 
circulation. In case they have not been eliminated through the kidneys, recirculating 
AGE peptides can generate new AGE products that react with other plasma or tissue 
components. At this stage, glycation becomes an autonomic process, which 
significantly accelerates the progress of the complications (Turk, 2001). 
Free radicals and AGE inhibitors 
Scavenging of free radicals by preventing radical formation and intercepting 
radical from further activity are done by antioxidants as key line of defense 
(Cotgreave et al, 1998). Antioxidant defenses are of two types. The defenses that 
directly scavenge H2O2 and 'OH are known as primary antioxidant defense. Secondary 
antioxidant defences consist of the repair mechanisms that act on biomolecules that 
have undergone oxidative damage. 
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The major antioxidants which are endogenous include superoxide dismutase 
(SOD) which removes O2', catalase that converts H2O2 to H2O and O2, and 
glutathione peroxidase, which helps with H2O2 removal and prevents hydroxyl radical 
(OH) formation (Halliwell and Gutteridge, 1999). Lipoic acid has the unique ability 
to regenerate several other antioxidants such as vitamin E and vitamin C (Packer and 
Coleman, 1999). Vitamin C, the major plasma antioxidant, is a scavenger of many 
ROS and reactive nitrogen species, and is capable of regenerating tocopherol from its 
radical (Maxwell, 1995; Halliwell and Gutteridge, 1999). Metal chelators ethylene 
diaminetetraaceticacid (EDTA) and diethylene triaminepentaaceticacid (DTPA) 
sequester the trace amounts of transition metal and hence inhibit oxidation (Wolff and 
Dean, 1987). Maimitol and benzoic acid are hydroxyl radical scavengers, which 
inhibit protein fragmentation (Hunt et al, 1988; Nagai et al, 1997). There are 
numerous other dietary sources of antioxidants (McDermott, 2000). 
AGE inhibitors are of three types. First, carbonyl trapping agents like 
aminoguanidine that attenuate carbonyl stress. Second, metal-ion chelators like 
pyridoxamine, DTPA, which suppress glycoxidation reactions and third, crosslink 
breakers like thiazolium salts (ALT-711) that reverse AGE crosslinks. Chelators, 
sulfhydryl compounds, antioxidants and aminoguanidine inhibit formation of 
glycoxidation products, generation of fluorescence and cross-linking of collagen 
without significant effect on the extent of glycation of the protein (Fu et al, 1994). 
While use of aminoguanidine was discontinued because of its side effects, 
pyridoxamine and ALT-711 were shown to be promising AGE inhibitors (Reddy and 
Beyaz, 2006). The blocking of interaction between AGEs and RAGE by usage of 
soluble RAGE (sRAGE), which does not involve signal transduction, has therapeutic 
applications in animal models (Park et al, 1998; PuUerits et al, 2005). 
Autoimmunity 
In order to elicit an immune response, a molecule must be recognized as 
nonself by the biological system. When an antigen is introduced into an organism, the 
degree of immunogenicity depends on the degree of its foreignness; generally the 
greater the phylogenetic distance between two species, the greater the structural 
disparity between them. Bovine serum albumin is strongly immunogenic when 
injected into rabbit (Goldsby et al, 2003). 
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The lack of an immune response to self when responses to environmental 
antigens are retained is due to immunological tolerance. The role of tolerance, or lack 
of tolerance, is important to the understanding of autoimmune diseases and 
transplantation immunobiology (Goldsby et al, 2003). A loss of natural tolerance to 
self underlies all autoimmune diseases. Many more individuals develop autoimmune 
phenomena than autoimmune disease. Immune-mediated Type 1 diabetes mellitus 
results from an organ-specific autoimmune-mediated loss of insulin secreting P cells. 
This chronic destruction process involves both cellular and hormonal components 
detectable in the peripheral blood, months or even years, before the onset of clinical 
diabetes (Kukreja and Maclaren, 1999). 
Amadori products of HSA are found to be immunogenic and Type 1 diabetic 
patients with retinopathy and nephropathy have higher Amadori albumin levels than 
did those without it (Cohen and Ziyadeh, 1994; Schalkwijk et al, 1999). Proteins 
containing AGEs are highly immunogenic and CML is one of the major epitopes 
recognized by anti-AGE antibodies (Reddy et al, 1995; Ikeda et al, 1996). The 
presence of CML-BSA antibodies in the serum of streptozotocin-diabetic rats as well 
as in a small number of diabetic patients have been reported (Shibayama et al, 1999). 
AGE can exert their immunogenicity, which demonstrate the presence of AGEs-
immune complexes (AGE-ICs) in the diabetic patients that may play a role in the 
atherogenesis (Turk et al, 2001). Interactions of AGE autoantibodies with AGEs as a 
continuously produced antigen result in the formation of AGE-ICs that may play role 
in diabetic complications (Jakus and Rietbrock, 2004). Autoantibodies against N -^
carboxyethyllysine (CEL) in human lens proteins are found in diabetic patients 
(Ahmed e? a/., 1997). 
Diabetes mellitus 
Diabetes mellitus is a syndrome characterized by disordered metabolism and 
hyperglycemia resulting from defects in insulin secretion, low levels of insulin or 
insulin resistance. In diabetes mellitus, low insulin levels prevent cells from absorbing 
glucose. As a result, glucose builds up in the blood. When glucose-laden blood passes 
through the kidneys, all the excess glucose cannot be absorbed. This excess glucose 
secreted in the urine, accompanied by water and electrolytes; ions required by cells to 
regulate the electric charge and flow of water molecules across the cell membrane. 
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This causes polyurea, polydipsia and weight loss as classical symptoms of the 
diabetes. These symptoms together with a random plasma glucose concentration > 
11.1 mmol/L (200 mg/dL) is sufficient for the diagnosis of diabetes mellitus although 
fasting plasma glucose is the most reliable and convenient test for identifying diabetes 
in asymptomatic individuals (Powers, 2005). 
In diabetic patients, increased level of blood glucose correlates with increased 
formation of ketoamine. Measurement of blood glucose gives only the current glucose 
concentration as transient or short term indicator. The ketoamine value is the mean 
blood glucose concentration over preceding 2 to 3 weeks as medium term indicator 
while measurement of glycated hemoglobin (HbAlc) represents mean glucose 
concentration over a 6 to 8 week period as long term indicator. Though there is a 
strong correlation between elevated plasma glucose and HbAlc, the relationship 
between the fasting plasma glucose (FPG) and HbAlc in individuals with normal 
glucose tolerance and mild glucose tolerance is less clear and thus the use of HbAlc 
is not currently recommended for the diagnosis of diabetes (Powers, 2005). 
The World Health Organization recognizes three main forms of diabetes 
mellitus: Type 1, Type 2 and gestational diabetes, which have different causes and 
population distributions. While, ultimately, all forms are due to the beta cells of the 
pancreas being unable to produce sufficient insulin to prevent hyperglycemia, the 
causes are different (Rother, 2007). Type 1 diabetes is usually due to autoimmune 
destruction of the pancreatic beta cells. Type 2 diabetes is characterized by insulin 
resistance in target tissues, this causes a need for abnormally high amounts of insulin 
and diabetes develops when the beta cells cannot meet this demand. Gestational 
diabetes is similar to Type 2 diabetes in that it involves insulin resistance; the 
hormones of pregnancy can cause insulin resistance in women genetically predisposed 
to developing this condition. 
Diabetes can cause many complications. Acute complications of diabetes 
include diabetic ketoacidosis (DKA) and hyperglycemic hyperosmolar state (HHS). 
Hypoglycemia is most commonly caused by drugs used to treat diabetes mellitus or 
by exposure to other drugs, including alcohol. Serious long-term or chronic 
complications include cardiovascular disease, chronic renal failure, retinal damage, 
nerve damage and microvascular damage, which may cause impotence and poor 
healing. Poor healing of wounds, particularly of the feet, can lead to gangrene, which 
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may require amputation. Around 4 million deaths per year are caused due to 
conditions directly or indirectly associated with diabetes. 
Epidemiology 
According to the World Health Organization (WHO), at least 177 million 
people worldwide suffer from diabetes in 2000. Its incidence is increasing rapidly and 
it is estimated that by the year 2030, this number will rise to >360 million. The 
International Diabetes Federation (IDF) estimated about 194 million people 
worldwide to have diabetes in 2003 and is expected to increase to about 333 million 
by 2025. Diabetes mellitus occurs throughout the world, but is more common 
(especially Type 2) in the more developed countries. The greatest increase in 
prevalence is, however, expected to occur in Asia and Africa, where most patients 
will likely be found by 2030. The major risk factors of diabetes mellitus are age, 
obesity, lack of exercise, along with a strong genetic predisposition. 
For at least 20 years, diabetes rates in North America have been increasing 
substantially. In 2005, there are about 20.8 million people with diabetes in the United 
States alone. According to the American Diabetes Association, there are about 6.2 
million people undiagnosed and about 41 million people that would be considered 
prediabetic. 
India now being termed the "diabetes capital of the world" as it leads the 
world with largest number of diabetic subjects. WHO report shows that 32 million 
people in India had diabetes in the year 2000 and is expected to increase to about 80 
million by 2030. The International Diabetes Federation (IDF) estimated the total 
number of diabetic subjects to be around 35.5 million in India in 2003 and this is 
further set to rise to 73.4 million by the year 2025. 
Type 1 diabetes mellitus 
Type 1 or insulin dependent diabetes mellitus, also knovm as juvenile onset 
diabetes mellitus is characterized by loss of the insulin-producing beta cells of the 
islets of Langerhans in the pancreas, leading to a deficiency of insulin and 
hyperglycemia. The main cause of this beta cell loss is a T-cell mediated autoimmune 
attack (Rother, 2007). A number of antibodies have been detected as the markers of 
autoimmune diabetes. These include islet cell autoantibodies (ICA), insulin 
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autoantibodies (lAA) (Atkinson et al, 1992), glutamic acid decarboxylase 65 
(GAD65) autoantibodies (Jun et al, 2002), antibodies to tyrosine phosphatases IA-2 
and IA-2P (Lan et al, 1996; Lu et al, 1996). In over 90% of the cases. Type 1 
diabetes mellitus is immune mediated and in less than 10% of the cases it is 
idiopathic. Most affected people are otherwise healthy and of a healthy weight when 
onset occurs. Sensitivity and responsiveness to insulin are usually normal, especially 
in the early stages. 
It usually occurs in younger age group with highest incidence in 10-14 years 
age-group. The incidence of Type 1 diabetes shows little bias upto 15 years of age, 
but more males are diagnosed in early adult life. The lower prevalence of lAA in 
adolescent females implies sex specific modulation of the autoimmune process during 
puberty (Williams et al, 2003). The principal treatment of Type 1 diabetes, even from 
the earliest stages, is replacement of insulin combined with carefiil monitoring of 
blood glucose levels using blood testing monitors. Without insulin, diabetic 
ketoacidosis can develop and may result in coma or death. Emphasis is also placed on 
lifestyle adjustments (diet and exercise) though these cannot reverse the loss. 
Genetic susceptibility to Type 1 diabetes mellitus involves multiple genes. The 
major susceptibility gene for Type 1 diabetes mellitus is located in the HLA region on 
chromosome 6. Polymorphisms in the HLA complex account for 40 to 50% of the 
genetic risk of developing Type 1 diabetes mellitus. This region contains genes that 
encode the class II MHC molecules. Most individuals with Type 1 diabetes mellitus 
have HLA DR3 and/or DR4 haplotype (Powers, 2005). 
Even in the presence of the above predisposing factors the pathogenic process 
might not get initiated. Detailed studies have shown that a toxic or infectious insult is 
required for triggering the autoimmune destruction of P-cells of pancreas. Coxsackie-
B virus, mumps virus, congenital rubella and cytomegalovirus and more recently 
hepatitis C virus have been shown to be related to Type 1 diabetes in this regard 
(Forrest et al, 1971; King et al, 1983; Pak et al, 1988; Karjalainen et al, 1998; Chen 
et al, 2005). Molecular mimicry has been closely linked to Type 1 diabetes mellitus 
in this respect where an autoimmune response is developed either against pancreatic 
antigen or against molecules of B cells resembling the viral protein. 
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Type 2 diabetes mellitus 
Type 2 or non-insulin dependent diabetes mellitus also known as adult onset 
diabetes mellitus is the most common form of diabetes mellitus. It is also characteized 
by hyperglycemia and abnormalities of insulin resistance or reduced insulin 
sensitivity, combined with reduced insulin secretion and excessive hepatic glucose 
production. The defective responsiveness of body tissues to insulin almost certainly 
involves the insulin receptor in cell membranes. The autoantibodies of Type I 
diabetes mellitus especially GAD may also occur in up to 10% of adults initially 
classified as Type 2 diabetes in a condition known as Latent Autoimmune Diabetes in 
Adults (LADA) or Type 1.5 diabetes. The disease process in LADA patients is similar 
to that in Type 1 diabetes in that they share some HLA genetic susceptibility and 
some Type 1 diabetes associated autoantibodies (Agardh et ah, 2005). 
In the early stage the predominant abnormality is reduced insulin sensitivity, 
characterized by elevated levels of insulin in the blood. At this stage hyperglycemia 
can be reversed by a variety of measures and medications that improve insulin 
sensitivity or reduce glucose production by the liver. As the disease progresses the 
impairment of insulin secretion worsens and therapeutic replacement of insulin often 
becomes necessary. 
The pathogenesis of insulin resistance is currently focussed on PI-3 kinase 
signalling defect, which reduces translocation of GLUT 4 to the plasma membrane. 
Another emerging theory proposes that increased levels of free fatty acids, a common 
feature of obesity, may contribute to pathogenesis. Free fatty acids can impair glucose 
utilization in skeletal muscles, promote glucose production by the liver and impair P-
cell funcion (Powers, 2005). 
Type 2 diabetes may go urmoticed for years because visible symptoms are 
typically mild, non-existent or sporadic and usually there are no ketoacidotic 
episodes. However, severe long-term complications can result from unnoticed Type 2 
diabetes, including renal failure due to diabetic nephropathy, vascular disease 
(including coronary artery disease), vision damage due to diabetic retinopathy, loss of 
sensation or pain due to diabetes neuropathy and liver damage from non-alcoholic 
steatohepatitis. 
A heterogenous group of factors are involved in the pathogenesis of this form 
of diabetes. Obesity has a strong predisposing factor for the development of insulin 
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resistance and hence Type 2 diabetes mellitus (Bogardus et al, 1985). Moreover, 
visceral obesity and not subcutaneous disposition of fat has been held responsible for 
giving rise to insulin resistance (Kissebah et al, 1982). Genetic predisposition is also 
a strong predisposing factor (Byrne et al, 1996). 
Asian Indians are more prone to Type 2 diabetes and premature coronary 
artery disease due to "Asian Indian Phenotype". The phenotype refers to certain 
unique clinical and biochemical abnormalities in Indians which include increased 
insulin resistance, greater abdominal adiposity i.e., higher waist circumference despite 
lower body mass index, lower adiponectin and higher high sensitive C-reactive 
protein levels (Mohan et al, 2007). 
Type 2 diabetes is a polygenic disorder with multiple genes located on 
different chromosomes contributing to its susceptibility and numerous environmental 
factors interact with these genes to produce the disorder. Single gene defects like 
maturity onset diabetes of the young (MODY) cause only a minority of cases of Type 
2 diabetes. There are certain genes which predispose Indians to diabetes while other 
genes (for example Pro 12 Ala polymorphism of PPAR gamma gene) which afford 
protection against diabetes and insulin resistance to Caucasians, do not appear to 
protect Indians (Radha and Mohan, 2007). Individuals with a parent with Type 2 
diabetes mellitus have an increased risk of diabetes; if both parents have Type 2 
diabetes mellitus, the risk is approximately 40%. The concordance of Type 2 diabetes 
mellitus in identical twins is between 70-90% (Powers, 2005). 
Enviromnental factors such as nutrition and physical activity further modulate 
phenotypic expression of the disease. Genetic defect in insulin secretion or action may 
not manifest itself unless an environmental effect or another genetic defect such as 
obesity is superimposed (Shervin, 2001). 
ROS in diabetes mellitus 
The overproduction of ROS lowered antioxidant defense and alterations of 
enzymatic pathways in humans with poorly controlled diabetes mellitus (Jakus, 2000). 
Diabetic individuals may exhibit elevated levels of iron and free copper ions (Cutler, 
1978; Mateo et al, 1978), which in the presence of glycated proteins in vitro have 
been shown to generate free radicals (Hunt, 1994; Nagai et al, 1997). The 
accumulation of glycated material in tissues that contain free copper ion, contribute to 
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the generation of free radical mediated damage. The formation of a-dicarbonyl 
compounds is known to be an essential step for the cross hnking of proteins and 
subsequent free radical generation (Rahbar and Figarola, 2003). In the presence of 
oxidative stress, glycation of proteins by methylglyoxal is enhanced. This may 
underlie the link of glycation and oxidative stress with diabetic complications, and 
may also contribute to the pathological processes of ageing (Harman, 1998). 
Hyperglycemia in the pathogenesis of diabetic complications 
In diabetic subjects, hyperglycemia leads to glycated and advanced glycated 
products and is widely recognized as the major cause of diabetic secondary 
complications (Table 1) due to overgeneration of ROS (Cai and Kang, 2001; 
Palm et al, 2003). 
Diabetic retinopathy 
It is characterized by increased proliferation of blood vessels, haemorrhages 
and infarction affecting retina of the eye accompanied by thickening of the capillary 
basement membrane and increased permeability of the capillaries. AGEs have been 
detected in retinal blood vessel walls and contribute towards vascular occlusion and 
increased permeability of retinal endothelial cells causing vascular leakage 
(Beisswenger et al, 1995; Chibber et al, 1997). AGEs exert their effect on 
microvascular endothelial cells and pericytes by upregulating levels of their RAGE 
mRNA (Tanaka et al, 2000). AGEs may cause loss of pericytes and death of 
endothelial cells in diabetic retinopathy. Retinal cells exposed to AGEs cause 
upregulation of vascular endothelial cell grow1:h factor (VEGF), which in turn, 
stimulates angiogenesis and neovascularization, and accounts for the pathogenesis of 
proliferative retinopathy (Yamagishi et al, 2002). AGEs stimulate secretion of IL-6 
from human retinal cells which can induce angiogenesis by increased expression of 
VEGF (Nakamura etal, 2003). 
Fructoselysine, an initial Amadori adduct in collagen in Type 1 diabetic 
patients was independently associated with retinopathy (McCance et al, 1993). 
Elevated concentrations of Amadori albumin in animal have been implicated in the 
development of diabetic retinopathy (Clements et al, 1998). 
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Diabetic nephropathy 
It is clinically manifested by proteinuria progressing to renal insufficiency and 
histopathologically by mesangial expansion and glomerular basement membrane 
thickening. Hyperglycemia and AGEs increase the release of transforming growth 
factor-P (TGF-p) and may contribute towards thickening of basement membrane, 
altered filtration and ultimately loss of glomerular function (Monnier et al., 1992). 
Serum AGE levels reflect the severity of diabetic nephropathy and their measurement 
can predict the histopathological conditions (Berg et al., 1997). 
Circulating serum AGE level is so markedly increased in patients with 
diabetic nephropathy and renal insufficiency that it cannot be cleared by the kidneys 
(Turk, 2001). Serum AGEs include both serum proteins that have been modified by 
advanced glycation and low molecular weight AGE peptides (Shimoike et al., 2000). 
Increased concentrations of serum AGEs in nephropathy could account for the rapid 
development of atherosclerosis (Bucala and Vlassara, 1995). Some studies have 
shown that advanced nephropathy develops in transgenic mice that over-express 
RAGE in vascular cells (Yamamoto et ai, 2001). Fructoselysine (Amadori product) 
in collagen was also independently associated with nephropathy in Type 1 diabetic 
patients (McCance et ai, 1993). 
Diabetic atherosclerosis 
It is characterized by deposition of atherosclerotic plaques in arterial walls and 
myocardial infarction. Glycated LDL may be responsible for the hyperlipidemia and 
accelerated foam cell formation in diabetic patients (Lopes-Virella et al., 1988). 
Diabetic patients have high LDL-AGE levels and their reduced serum clearance. 
Increased oxidation of LDL leads to increase in this atherogenic oxidized LDL in 
diabetes during glycation and AGE formation (Bucala, 1997). Glycated HDL has an 
indirect role in atherosclerotic plaque formation in which AGEs have been detected 
(Hedrick et al., 2000). AGEs promote these plaques through secretion of several 
cytokines including insulin-like growth factor-I (IGF-I) and platelet-derived growth 
factor (PDGF) (Vlassara, 1996). 
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TABLE 1 
Role of AGEs and AGE receptors in the pathogenesis of diabetic complications. 
Source: Turk, 2001. 
Diabetic atherosclerosis 
Vascular tissue AGE accumulation -> protein crosslinking -> oxidative 
damage 
Increased vascular matrix -> thickening and narrowing of lumen 
Increased endothelial cell permeability and procoagulant activity -> 
thrombosis 
Mononuclear cell chemotaxis/activation -> cytokine and growth factor release 
Increased macrophage uptake of AGE-LDL ->• atheroma 
Diabetic kidney disease 
Increased mesangial matrix secretion 
Increased basement membrane deposition 
Increased vascular permeability 
Increased growth factor secretion 
Glomerular hypertrophy -> glomerulosclerosis 
Diabetic retinopathy 
Increased cell penneability -^ vascular leakage and retinal damage 
Increased vessel wall thickening -^ occlusion -^ retinal ischemia -> 
neovascularization 
Increased intravascular coagulation -> occlusion ->• retinal ischemia -> 
neovascularization 
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A study on diabetic mice showed that deficiency of apolipoprotein E (apo E) 
promotes atherosclerosis and increased expression of RAGE and AGEs (Park et al., 
1998). Approximately 2% to 5% of apo B in the plasma of diabetic persons are 
glycated, compared with about 1% in the plasma from nondiabetic control subjects 
(Turk, 2001). 
Objectives of the present study 
Non-enzymatic glycation of proteins with generation of free radicals occur by 
covalent interaction between sugar and free amino groups of proteins. The early and 
advanced glycation end products are known to be involved in the pathogenesis of 
diabetes and associated secondary complications. These products and free radicals are 
known to cause severe protein damage resulting in major structural alterations, which 
is implicated either through their functional disability or these being highly 
immunogenic. 
Since glycation of proteins primarily occurs at intrachain lysine residues, the 
present study was planned to study the effect of glucose and reactive oxygen species 
(OH) on poly-L-lysine, a homopolymer of lysine residues. It was first modified with 
glucose to obtain a high yield of Amadori products (an early glycation product) and 
then the glycated poly-L-lysine was subjected to hydroxyl radical (OH) generated by 
Fenton reaction. Native and modified poly-L-lysine were then characterized by 
various biochemical, biophysical and immunological studies. 
Antigenicity of native and modified poly-L-lysine was probed by inducing 
antibodies in rabbits and assessed by direct binding ELISA. The specificity of the 
induced antibodies was evaluated by competition ELISA and gel retardation assay. 
The serum of patients with diabetes mellitus contains a variety of autoanfibodies that 
react with a variety of protein and nuclear antigens. In order to assess the possible role 
of glycated poly-L-lysine and ROS-glycated poly-L-lysine in diabetes and associated 
secondary complications, serum samples of diabetes patients were investigated for the 
presence of antibodies against native and modified forms of poly-L-lysine. The 
polyclonal anti-glycated- and anti-ROS-glycated-poly-L-lysine antibodies could be 
used as a probe to detect glycation and ROS modification of lysine rich proteins in 
diabetes patients as well as in healthy subjects. 
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Materials & Methods 
MATERIALS 
Poly-L-lysine, Millipore filter (0.2 p,m), diethylene triaminepentaacetic acid 
(DTPA), catalase, superoxide dismutase (SOD), bovine serum albumin (BSA), 
protein A-Sepharose CL-4B (5 ml pre-packed column), agarose, coomassie brilliant 
blue G-250, anti-human and anti-rabbit IgG-alkaline phosphatase conjugate, p-nitvo-
phenyl phosphate, Tween-20, Freund's complete and incomplete adjuvants were 
purchased from Sigma Chemical Company, U.S.A. D-Glucose and sodium 
borohydride (NaBH4) were obtained from Merck (India). Acrylamide, bisacrylamide, 
ammonium persulphate, sodium dodecyl sulphate (SDS) and nitrobluetetrazolium 
(NET) were from SRL Pvt. Ltd., India. N,N,N'N'-Tetramethylethylenediamine 
(TEMED) was obtained from BDH Chemicals Ltd., England. Polystyrene microtitre 
flat bottom ELISA plates and modules were purchased from NUNC, Denmark. Silver 
nitrate, hydrogen peroxide, methanol, isopropanol, formaldehyde, glacial acetic acid 
and glycerol were from Qualigens Fine Chemicals, India. All other 
chemicals/reagents were of the highest analytical grade available from commercial 
sources. 
Collection of sera and blood samples 
Blood samples from diabetes mellitus patients were collected from outdoor 
and indoor patients under treatment at the Jawaharlal Nehru Medical College 
Hospital, A.M.U., Aligarh. Samples from age/sex matched healthy individuals were 
used as nonnal control. Sera, separated from the blood samples, were heated at 56 °C 
for 30 min. to inactivate complement proteins and stored in aliquots at -20 °C with 1% 
sodium azide. 
METHODS 
Protein estimation by Bradford (dye-binding) method 
This assay is based on colour change observed when an acidic dye binds 
hydrophobically to protein having positively charged groups (Bradford, 1976). In the 
environment of these positively charged groups, protonation is suppressed and a blue 
colour is observed (Jimax = 595 nm). 
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Dye preparation 
100 ^g of coomassie brilliant blue G-250 was dissolved in 50 ml of 95% 
ethanol and 100 ml of 85% (v/v) orthophosphoric acid was added to it. The resulting 
solution was diluted to a final volume of 1.0 litre and filtered through a Whatman No. 
1 filter paper to remove undissolved particles. 
Protein assay 
To 1.0 ml solutions, containing 10-100 ^g polypeptide, 5.0 ml of dye solution 
was added and the contents were mixed by vortexing. The absorbance was read at 595 
nm after 5 min., against a blank reagent. 
Modification of poly-L-Iysine by glucose 
For the preparation of high contents of glycated Amadori product but an 
extremely low level of AGEs, poly-L-lysine (Img/ml) was incubated for 7 days at 37 
°C with 50 mM glucose in 20 mM sodium phosphate buffer (pH 7.4) in the presence 
of 1 mM diethyienetriaminepentaacetic acid (DTPA) (Nagai et. al., 1997). The sample 
was then extensively dialyzed against sodium phosphate buffer (pH 7.4) and stored at 
-20 "C before use. Poly-L-lysine dissolved in the same buffer and incubated in the 
above described conditions was used as control. 
Same procedure was adopted for the giycation of IgG, HSA and histone. 
Modification of glycated poIy-L-lysine by reactive oxygen species (ROS) 
Glycated poly-L-lysine was incubated for 1 hr at 37 °C with lOmM anhydrous 
FeCL in the presence of 10 mM H2O2 in 20 mM sodium phosphate buffer (pH 7.4), 
(Nagai et al, 1997). Excess of hydrogen peroxide was removed by extensive dialysis 
at 4 °C against phosphate buffered saline (PBS). This condition would be favourable 
for the generation of "OH radical. 
Glycated IgG, HSA and histone were also modified by ROS as mentioned 
above. 
Effect of quenchers on ROS-glycated poIy-L-lysine 
The effect of individual free radical quenchers like SOD (an O2' scavenger) at 
500 units, EDTA (a metal chelator) at 5 mM, catalase (an H2O2 scavenger) at 500 
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units and mannitol (an OH scavenger) at 100 mM, on Fe^ "" induced ROS modification 
of Amadori poly-L-lysine was determined by carrying out the reaction in the 
presence of specific quencher. 
Amadori product / ketoamine estimation 
The level of Amadori product in the native and modified poly-L-lysine was 
determined by an established colorimetric procedure (Johnson et al, 1982) using 
nitroblue tetrazolium (NBT) with minor modification. Native, glycated and ROS-
glycated poly-L-lysine samples (100 jxl) were added to the wells of 96 well microtitre 
plate in duplicate. 100 |il of NBT reagent (250 \M in 0.1 M carbonate buffer, pH 
10.35) was added to each well and incubated at 37 °C for 2 h. The reduction rate of 
NBT was monitored by increase in absorbance at 525 nm. The content of Amadori 
products was determined using an extinction coefficient of 12640 cm"' M'' for 
monoformazan (Mironova et al, 2005). 
Determination of 5-hydroxymethylfurfuraI (HMF) 
The thiobarbituric acid (TBA) reaction for determining the formation of 5-
hydroxymethylfurfural (HMF) from Amadori products of glycated poly-L-lysine was 
employed as described previously (Fluckiger and Winterhalter, 1976), with slight 
modifications. Briefly, I ml each of native and modified poly-L-lysine samples were 
mixed with 1 M oxalic acid and incubated at 100 °C for 2 hr (10). The protein from 
the assay mixture was removed by precipitation with 40% trichloroacefic acid. TBA 
(0.05 M) was added to protein free filtrate and incubated at 40 °C for 40 min. The 
colour was developed and amount of HMF was calculated using molar extinction 
coefficient value of 4 x lO '^at 443 nm for HMF. 
Spectrophotometry 
Absorbance (A) of native and modified poly-L-lysine samples was recorded in 
the wavelength 190-400 nm range on a Shimadzu UV-1700 spectrophotometer using 
1 cm-path length cuvette. The increase in absorbance (hyperchromicity) was 
calculated using the following equation 
% H y p e r c h r o m i c i t y = (A modified poly-L-ljsme - A native pol\-L-lysine / A modified poly-!.-lysiiie) ^ 1UU 
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Fluorescence measurements were performed on Shimadzu RF 5301-PC 
spectrofluorophotometer. The fluorescence spectra were recorded at 25 ± O.TC in a 1 
cm-path length cuvette with a slit width of 5 nm. The native and modified poly-L-
lysine samples were excited at different wavelengths (290-410 nm) and the emission 
spectra were recorded in the range (300-500 nm) to obtain the maximum intensity 
peak. Loss of fluorescence intensity (PI) was calculated using the following equation 
/o L o s s 01 r l — ( r i native poly-L-lysine " rl modified poly-L-lysine' -rl native poly-L-iysinej iOU 
Circular dichroism spectropolarimetry 
CD of native and modified poly-L-lysine was measured on a Jasco J-810 
spectropolarimeter equipped with a temperature controlled sample cell holder. Spectra 
were taken with a scan speed of 20 nm/min at a response time of 1 sec. Each spectrum 
was the average of two scans. Far-UV CD spectra were taken at protein concentration 
of 3.0 p,M with a cell of 1 mm path length. For each sample, buffer was used as blank. 
The results in mean residual ellipticity (MRE), expressed in deg.cm .mol", as 
MRE = CD/(10xnxlxCp) 
where CD is in milli-degree (mdeg), n is the number of amino acid residues, 1 is the 
path length of the cell and Cp is the mole fraction. 
FT-IR and NMR Spectrometry 
FT-IR spectra of the samples were obtained on a Shimadzu 8201-PC 
spectrometer with a resolution of 4 cm"'. Samples to be analyzed on FT-IR 
spectrophotometer were first lyophilized and prepared as KBr pellets. 
' H NMR spectra were recorded on a Bruker DRX-300 MHz FT NMR 
spectrometer. All samples for NMR spectroscopy were first lyophilized and prepared 
using DMSO as a solvent. The chemical shifts in parts per million (ppm) are 
expressed with respect to tetramethylsilane (TMS) as a reference. 
Reduction of glycated poly-L-lysine with NaBH4 
Glycated poly-L-lysine was reduced with 200-300-folds molar excess of 
sodium borohydride (NaBH4) in phosphate buffer, pH 8.0, using a previously 
described procedure (Njoroge et ai, 1988). Excess borohydride was destroyed by 
slow addition of IN HCl. 
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Immmunization schedule 
The immunization of random bred, female New Zealand white rabbits was 
performed as described previously (Dixit et al, 2005). Briefly, rabbits were 
immunized intramuscularly at multiple sites with 100 fig of each of native and 
modified poly-L-lysine, emulsified with an equal volume of Freund's complete 
adjuvant. The animals were boosted in Freund's incomplete adjuvant at weekly 
intervals for 6 weeks with the same amount of antigen. Test bleeds were performed 7 
days post boost and antibody titre was determined. Blood was taken out from the ear 
vein and serum separated from the blood (preimmune and immune) was heated at 56 
°C for 30 min to inactivate complement proteins and stored at -20 °C with 0.1% 
sodium azide as preservative. 
Isolation of IgG by Protein A-Sepharose 
Immunoglobulin G (IgG) was isolated by affinity chromatography on Protein 
A-Sepharose CL-4B column (Dixit et al, 2005). Serum (0.5 ml), diluted with an 
equal volume of PBS, pH 7.4 was applied to the column, previously equilibrated with 
the same buffer. The wash through was recycled 2-3 times. Unbound IgG was 
removed by extensive washing with PBS, pH 7.4. The bound IgG was eluted with 
0.58% acetic acid in 0.85% sodium chloride and neutralized with 1 ml of 1.0 M Tris-
HCL, pH 8.5. The fractions (3 ml) were read at 251 and 278 nm. The IgG 
concentration was determined considering 1.40 OD280 = 1-0 mg/ml. The isolated IgG 
was dialysed against PBS, pH 7.4 and stored at -20 °C with 0.1 % sodium azide. 
ELISA 
The following reagents and buffers were prepared in distilled water and used 
in ELISA. 
Antigen coating buffer 
50 mM carbonate-bicarbonate, pH 9.6 
Tris buffered saline (TBS) 
10 mM Tris, 150 mM NaCl, pH 7.4 
Tris buffered saline-TM>een~20 (TBS-T) 
20 mM Tris, 150 mM NaCl, 2.68 mM KCl, 0.05% Tween-20, pH 7.4 
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Carbonate-bicarbonate buffer 
15 mM sodium carbonate, 35 mM sodium bicarbonate, 2 mM MgCl, pH 9.6 
Substrate 
500 figp-nkrophenyl phosphate in I ml carbonate-bicarbonate buffer. 
Enzyme linked immunosorbent assay (ELISA) was carried out on polystyrene 
plates with slight modification (Ali and Alam, 2002). Polystryrene polysorp 
immunoplates were coated with 100 ^I of native or modified poly-L-lysine (10 ^g/ml) 
in antigen coating buffer for 2 h at 37 °C and overnight at 4 °C. Each sample was 
coated in duplicate and half of the plate devoid of antigen coating served as control. 
Unbound antigen was washed twice with TBS-T and unoccupied sites were blocked 
with 150 [il of 2% fat free milk in TBS for 4-6 h at 37 °C. After incubation the plates 
were washed three times with TBS-T. Test serum, serially diluted in TBS-T, was 
added t o each well (100 ^1/well) and was left for 2 h at 37 °C and overnight at 4 °C. 
After incubation, the plates were washed thrice with TBS-T and bound antibodies 
were assayed with anti-rabbit (or anti-human, for human autoantibodies) alkaline 
phosphatase conjugate in TBS. After incubation at 37 °C for 2 h, the plates were again 
washed three times with TBS-T and twice with distilled water and were subsequently 
developed using /?-nitrophenyl phosphate as substrate. The absorbance (A) of each 
well was monitored at 410 nm on an automatic microplate reader. Results have been 
expressed as mean of Atest~Acontroi-
Competition ELISA 
The antigenic specificity of the antibodies was determined by competition 
ELISA (Habib et al., 2005). Varying amounts of inhibitors (0-20 ng/ml) were mixed 
with a constant amount of antiserum or IgG. The mixture was incubated at room 
temperature for 2 h and overnight at 4 °C. The immune complex thus formed was 
coated in the wells instead of the serum. The remaining steps were the same as in 
direct binding ELISA. Percent inJiibition was calculated using the formula: 
Percent Inhibition = 1- (A inhibited / A uninhibited) >< 100 
Band shift assay 
For the visual detection of antigen antibody binding and immune complex 
formation, gel retardation assays were performed (Dixit and Ali, 2004). Immune 
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complexes were prepared by incubating constant amount of native and modified poly-
L-lysine with varying amounts of affinity purified diabetes IgG or immune IgG in 
PBS for 2 h at 37 °C and overnight at 4 °C. One-fourth of sample dye was added to 
the mixture and electrophoresed on 8% SDS-PAGE for 6 h with 80 V at 4 °C. The 
gels were visualized using silver nitrate staining. 
SDS-PAGE 
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis was performed 
by the tris-glycine buffer system of Laemmli (1970) using slab gel electrophoresis 
apparatus. Concentrated stock solution of 30% acrylamide containing 0.8% 
bisacrylamide, 1.0 M Tris (pH 6.8 and 8.8) and 10%o SDS were prepared and mixed in 
appropriate proportion to give the final required percentage. Samples were prepared in 
the sample buffer containing 1% (w/v) SDS, 10% (v/v) glycerol, 0.0625 M Tris, pH 
6.8 and 1% bromophenol blue as tracking dye. Electrophoresis was performed in 
electrophoresis buffer containing 0.025 M Tris and 0.2 M glycine till the tracking dye 
reached the bottom of the gel. 
Silver nitrate staining 
After electrophoresis the protein bands were fixed by rapidly immersing the 
gel in a mixture of 40%) methanol and 13.5%) formaldehyde for 10 min with instant 
shaking. The gel was washed twice with distilled water each time for 5 min. This was 
followed by incubation in 0.02%) sodium thiosulphate for 1 min and two times 
washing with distilled water at an interval of 20 sec. The washed gel was then 
immersed in 0.1 %o silver nitrate solution for 10 min and then rinsed with distilled 
water and the bands were developed with 280 mM solution of sodium carbonate 
containing 0.5%o formaldehyde and 0.02% sodium thiosulphate. After the appearance 
of brown colored band, the reaction was stopped by transferring the gel to a mixture 
of 10% acetic acid and 30% methanol solution for 5 min. It was again washed 4-5 
times with distilled water and finally stored in distilled water. 
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Results 
Determination of Amadori products 
NBT reactive ketoamine in a mixture of glucose and -NH2 containing 
biomolecules is a standard and reliable chemical parameter to confirm early glycation 
products. High content of Amadori product was prepared by 7 days incubation of 
poIy-L-lysine at 37 °C with 50 mM glucose in the presence of 5 mM DTPA in 20 mM 
sodium phosphate buffer (pH 7.4). ROS modification of glycated poly-L-lysine was 
done by incubating glycated poly-L-lysine for 1 hr at 37 °C with 5 mM anhydrous 
FeCb in the presence of 10 mM H2O2 in 20 mM sodium phosphate buffer (pH 7.4). 
As shown in Fig. 4, glycated poly-L-lysine yielded high content of ketoamine 
(9.4±0.8 mM) while ROS-glycated poly-L-lysine had a very low ketoamine content 
(1.8±0.4 mM). Native poIy-L-lysine showed almost a negligible amount of 
ketoamine. 
Determination of 5-HydroxymethylfurfuraI 
5-Hydroxymethylfurfural (HMF) that might have formed from hydrolysis of 
the Amadori product of glycated poly-L-lysine was estimated as thiobarbituric acid 
(TBA) reactive substance for the presence of glucose (hexose) moiety on glycated 
poly-L-lysine (Fig. 5). Loss in HMF content was observed for ROS-glycated poly-L-
lysine. The HMF content in glycated poly-L-lysine and ROS-glycated poly-L-lysine 
were calculated to be 10.4±1.0 jiM and 1.7±0.4 (^ M respectively while the poly-L-
lysine without glucose in the reaction mixture, taken as control, had almost negligible 
level of HMF. 
FAR-UV Spectra 
As shown in Fig. 6, the native and modified poly-L-lysine gave characteristic 
peak at 202 nm. Upon glycation and ROS modification, hyperchromicity was 
observed. Glycated poly-L-lysine and ROS-glycated poly-L-lysine samples 
respectively exhibited 59.2% and 78.9% hyperchromicity. The ROS-glycated poly-L-
lysine samples showed a new broad peak centered at 278 nm. Absorbance and percent 
hyperchromicity values of poly-L-lysine and modified poly-L-lysine are summarized 
in Table 2. 
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Fig. 6. Ultraviolet absorption spectra of po!y-L-lysine ( ), glycated poly-L-
lysine (—) and ROS-glycated poly-L-lysine ( ). 
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TABLE 2 
UV absorption data on poly-L-lysine and modified poly-L-lysine 
Wavelength Absorbance Percent 
(nm) Hyperchromicity 
PoIy-L-lysine 202 
Glycated poly-L-lysine 202 
ROS-glycated poly-L-lysine 202 
0.52 
0.84 
1.71 
— 
59.2 
78.9 
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Quenching studies on ROS-modified glycated poIy-L-iysine 
The ROS modification in the present study is a result of production of 
hydroxyl radical, a powerful oxidant. Its in vitro generation was confirmed by the use 
of quenchers of various radicals. We exploited SOD (O2 scavenger), EDTA (metal 
ion chelator), catalase (an H2O2 scavenger) and mannitol (OH scavenger) to study 
their quenching effect on the oxidation of glycated poly-L-lysine. When ROS 
modification was carried out in the presence of each of these quenchers, certain 
degree of inhibition of the modification was observed with individual quenchers (Fig. 
7). SOD had no significant inhibitory effect while both catalase and mannitol 
appeared to be strong inhibitors of the ROS modification causing 78.6% and 75.1% 
quenching respectively. EDTA also exhibited a marked inhibition (82.1%) of the ROS 
modification. 
Fluorescence Studies 
Fluorescence emission profiles of poly-L-lysine excited at different 
wavelengths (290-370 nm) were recorded to find out emission wavelength of 
maximum intensity which could be exploited to monitor changes in the modified 
poly-L-lysine. The fluorescence intensity of poly-L-lysine was maximum at an 
emission wavelength of 324 nm upon excitation at 290 mii. The modification of poly-
L-lysine did not alter its wavelength of maximum emission. Emission profiles of 
poly-L-lysine and their modified counterparts have been presented in Fig. 8. 
Glycation of amino groups of lysine residues in poly-L-lysine and ROS modification 
of glycated poly-L-lysine were evident from 42.0% and 68.3%) loss of intensity 
respectively. There was a slight increase in emission intensity of ROS-glycated poly-
L-lysine at 365 rmi. The fluorescence characterisfics of poly-L-lysine and modified 
poly-L-lysine have been presented in Table 3. 
Circular dichroic (c.d.) spectra 
Far-UV c.d. spectral profile used for rapid determination of protein's 
secondary structure is a useful technique for quick assessment of conformation. The 
amide chromophore of the peptide bonds in proteins gives c.d. spectra in far-UV 
range (200-250 nm). The characterisfic far-UV c.d. properties of proteins were 
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exploited to look into the secondary structure of poly-L-lysine at pH 7.4 and changes 
obtained upon glycation and hydroxy] radical modification. The far-UV c.d. profile of 
poly-L-lysine and its modified counterpart is shown in Fig. 9. Poly-L-lysine showed a 
far-UV c.d. spectrum characteristic of a random coil. Poly-L-lysine showed a positive 
c.d. at 217 nm and a negative c.d. at 200 nm. The c.d. spectrum of modified poly-L-
lysine showed significant changes in c.d. intensity and signals at 217 nm and 200 nm 
when compared to that of native poly-L-lysine. Glycated poly-L-lysine showed a 
negative c.d. both at 217 nm and 200 nm while ROS-glycated poly-L-lysine showed a 
negative c.d. at 217 nm and a positive c.d. at 200 nm. Both modified poIy-L-lysine 
showed a significant decrease in c.d. intensity at 217 nm and a significant increase in 
c.d. intensity at 200 nm. Mean residual ellipficity (MRE) values of non-modified and 
modified poly-L-lysine at 217 nm and 200 nm are presented in Table 4. These 
findings indicate alteration in the original conformation of poly-L-lysine and a partial 
destruction of the secondary structure of poly-L-lysine upon modification. 
IR Spectra 
The FT-IR spectra of poly-L-lysine (Fig. 10a) and modified poly-L-lysine 
(Fig. 10b and c) were determined by the position and intensity of bands of amide and 
other characteristic groups present in their structures. The band near 1062 cm"' in the 
poly-L-lysine spectrum corresponding to C-N bond of amines was more prominent 
and broad peaked in the spectra of glycated and ROS-glycated forms of poly-L-lysine. 
The band at 1625 in poly-L-lysine, related to amide 1 was shifted to 1653 and 1655 
cm" in glycated and ROS-glycated forms of poly-L-lysine respectively. The band at 
] 702 cm" corresponds to keto (C=0) group of Amadori products in glycated-pol)'-L-
lysine. The band at 1158 cm"' in the spectra of ROS-glycated poly-L-lysine can be 
assigned to methylene (CH2) group of AGEs. The band at 3391 cm" related to the 
side chain e-amino groups in poly-L-lysine was shifted to 3399 and 3401 cm with 
change of intensity in glycated and ROS-glycated counterparts of poly-L-lysine 
respectively. The important diagnostic IR bands con-esponding to poly-L-lysine and 
modified poly-L-lysine are compiled in Table 5. 
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Fig. 7. Effect of free radical scavengers on ROS induced modification of glycated 
poly-L-lysine. The 02* scavenger (SOD, 500 units); metal chelator (EDTA, 
5 mM); H2O2 scavenger (Catalase, 500 units); OH scavenger (Mannitol, 100 
mM) were used. 
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Fig. 8. Fluorescence emission spectra of poly-L-lysine ( ), glycated poly-L-
lysine (—) and ROS-glycated poly-L-lysine (— — —). Excitation 
wavelength was 290 nm. 
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TABLE 3 
Fluorescence characteristic of poIy-L-lysine and modified poIy-L-lysine 
Intensity (A.U.) Percent Loss 
in Intensity 
Poly-L-lysine 92.3 
Glycated poly-L-lysine 53.5 42.0 
ROS-glycated poly-L-Iysine 29.3 68.3 
Excitation and emission wavelengths were 290 and 324 nm respectively. 
TABLE 4 
CD characteristic of poly-L-lysine and modified poly-L-Iysine 
MRE at 217 nm MRE at 200 nm 
.2 „ „ i - K / , 2 1-K (deg.cm .mol') (deg.cm .mol") 
PoIy-L-lysine +86.27 -2124.28 
Glycated poly-L-lysine -17.92 -384.29 
ROS-glycated poly-L-lysine -25.76 +154.61 
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Fig. 10. Infrared spectra of poly-L-lysine (a), glycated poly-L-lysine (b) and ROS-
glycated poly-L-lysine (c). 
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TABLE 5 
Characteristic IR bands of poIy-L-lysine and modified poly-L-lysine in 
wavenumbers (cm"^ ) 
N-H C-N C=0 E-NH2 
Poly-L-lysine 1625 1062 - 3391 
Glycated 
poly-L-lysine 1653 1062" 1702 3399 
ROS-glycated 
poly-L-lysine 1655 1062*' - 3401 
b = broad band 
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NMR Spectra 
Resonance signals can be identified and characterized in ' H - N M R spectrum of 
poly-L-lysine (Fig. 11a) and modified poly-L-lysine (Fig. l ib and c), recorded in 
DMSO. In poly-L-lysine spectrum, the signals at 5 = 2.72 ppm and 6 = 3.16 ppm 
should be assigned to the chemical shifts of e-methylene (s-CHi) protons. The 
assignment of chemical shifts of p, y, 5-methylene protons is inferred from 
multiplicity of the resonance signals within a range of 1.10-1.92 ppm. The 
multiplicity of the signal is due to the J coupling between adjacent methylene protons. 
The signal at 8 = 2.5 ppm is due to DMSO. 
Determination and assignment of glycated lysine residue in glycated poly-L-
lysine and oxidation of glycated poly-L-lysine in ROS-glycated poly-L-lysine were 
undertaken by direct comparison of changes in the NMR spectra before and after 
modification. In the modified poly-L-lysine, the chemical shifts of 8-methylene 
protons were found at 8 = 2.8 ppm and 8 = 3.0 ppm with their multiple signals while 
the shift of a-methylene proton appeared at 8 = 4.2 ppm with multiple signal. In the 
spectrum of glycated poly-L-lysine the resonance signals within the range of 3.38-
3.62 ppm are assigned to the hydrogen atoms of glucose while with ROS-glycated 
poly-L-lysine these proton signals become more intense at 8 = 3.62 ppm due to 
oxidation of glycated poly-L-lysine. The appearance of other multiple and singlet 
resonance signal at 8 = 4.89 ppm in the spectra of glycated poly-L-lysine and ROS-
glycated poly-L-lysine respectively should be assigned to chemical shift of the 
methylene proton of glucose. The important 'H- NMR chemical shifts corresponding 
to poly-L-lysine and modified poly-L-lysine are presented in Table 6. 
Antigenicity of native and modified poly-L-lysine 
The antigenicity of native and modified poly-L-lysine was determined by 
inducing antibodies in rabbits against native poly-L-lysine, glycated poly-L-lysine and 
ROS-glycated poly-L-lysine. The antigenic specificity of induced antibodies was 
assayed by direct binding and competition ELISA. Binding of these antibodies was 
further ascertained by band shift assay. 
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Fig. 11. ' H - N M R spectra of poly-L-lysine (a), glycated poly-L-lysine (b) and ROS-
glycated poly-L-lysine (c). 
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TABLE 6 
Characteristic ^H-NMR chemical shifts (ppm) of poly-L-Iysine and modified 
poly-L-lysine 
Lysine Component Glucose Component 
Cg (CH2) Cp, y, 8 (CH2) Ci (CH2) C3,4,5,6 (CH, CH2) 
Poly-L-lysine 2.72', 3.16' 1.10-1.92 
Glycated 
poly-L-lysine 2.80"\ 3.00"^  - 4.89'" 3.38-3.62 
ROS-glycated 
poly-L-lysine 2.80"', 3.00"^  - 4.89' 3.62'^ ^ 
s = single signal 
m = multiple signal 
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Antibodies against native poly-L-lysine 
Native poly-L-lysine showed very low titre antibodies (<1:400) by direct 
binding ELISA (Fig. 12). The binding of pre-immune serum was almost similar to 
that of immune serum at low titres. In competition ELISA an inhibition of 28.3% was 
obtained at 20 |^ g/ml of the immunogen (Fig. 13). 
Antibodies against glycated poly-L-lysine 
Glycated poly-L-Iysine antiserum showed high titre antibodies (> 1: 12800) by 
direct binding ELISA. However, the binding of pre-immune serum was of low 
magnitude (Fig. 14). In competition ELISA, a maximum of 75% inhibition was 
observed at 20 p.g/ml and 50% inhibition was achieved only at 7.2 |ag/ml of the 
immunogen (Fig. 15). 
Purification and characterization of glycated poly-L-lysine immune IgG 
Immunoglobulin G was isolated from pre-immune and immune rabbit 
antiserum of glycated poly-L-lysine by affinity chromatography on Protein-A 
Sepharose column (Fig. 16). The purity of IgG was evaluated by SDS-polyacrylamide 
gel electrophoresis in the absence of a reducing agent. The purified IgG migrated as a 
single band on 7.5% polyacrylamide gel upon electrophoresis (Fig. 16 inset). 
Direct binding ELISA of the purified anti-glycated-poly-L-lysine IgG showed 
strong reactivity towards its immunogen (Fig. 17). However, the pre-immune IgG 
showed negligible binding. 
When glycated poly-L-lysine was treated with NaBH4, the reduced glycated 
poly-L-lysine showed an inhibition of 62.5% at 20 (ig/ml in comparison to non-
reduced glycated poly-L-lysine which caused 85.3% inhibition at 20 (^ g/ml in the 
activity of anti-glycated poly-L-lysine IgG (Fig. 18). 
Band shift assay 
The binding of glycated poly-L-lysine with affinity purified anti-glycated 
poly-L-lysine IgG was ascertained by band shift assay. Increasing concentrations of 
the IgG were incubated with a constant amount of the antigen for 2 hr at 37°C and 
overnight at 4°C. With the increasing concentration of the antibodies a proportional 
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Fig. 12. Direct binding ELISA of poly-L-lysine with preimmune (•) and immune 
(A) sera. Microtitre plates were coated with native poly-L-lysine (10 
|ig/ml). 
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Fig. 13. Inhibition ELISA of anti-poly-L-lysine immune (•) and preimmune 
(•) sera with native poly-L-lysine. Microtitre plates were coated with 
native poly-L-lysine (10 jig/ml). 
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Fig. 14. Direct binding ELISA of glycated poly-L-lysine with preimmune (•) and 
immune (A) sera. Microtitre plates were coated with glycated poly-L-
lysine (10 |ig/ml). 
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Fig. 15. Inliibition ELISA of anti-glycated poIy-L-lysine immune (•) and pre-
immune (•) sera with glycated poly-L-lysine. Microtitre plates were 
coated with glycated poly-L-lysine (10 p-g/ml). 
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Fig. 16. Elution profile of anti-glycated poly-L-lysine IgG on Protein-A Sepharose 
affinity column. Inset: SDS-PAGE of purified IgG on 7.5% 
polyacrylamide gel. 
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Fig. 17. Binding of affinity purified anti-glycated poly-L-lysine immune IgG (A) 
and preimmune IgG (•) to glycated poly-L-lysine. Microtitre plates were 
coated with glycated poly-L-lysine (10 (ig/ml). 
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Fig. 18. Inhibition ELISA of anti-glycated poly-L-lysine IgG binding to 
glycated poIy-L-lysine. The inhibitors were glycated poly-L-lysine (•) 
and NaBH4 reduced glycated poly-L-lysine (•). Microtitre plates were 
coated with glycated poly-L-lysine (10 )ig/ml). 
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Fig. 19. Band shift assay of anti-glycated poly-L-lysine IgG binding to glycated 
poly-L-lysine. Lane 1 contains anti-glycated poly-L-lysine IgG (10 |j,g). 
Lanes 2-5 contain increasing concentration of IgG (10, 20, 30 and 40 |ig) 
incubated for 2 hr at 37 °C and overnight at 4 °C with a constant amount 
of antigen (10 ng). 
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teease in the fotmarion of high molecular weight immune complexes resulted in the 
retarded mobih.y. as visualized by shifting of bauds towards the wells ,n the 
electrophoretic analysis (Fig. 19). 
Antibodies against ROS-glycated poly-L-lysine 
ROS-glycated poly-L-lysine antiserum showed high litre antibodies (> 1: 
12800) by direct binding ELISA. However, the binding of pre-immune serum was of 
low magnitude (Fig. 20). In competition ELISA, a maximum of 70.8o/o inhibition was 
observed at 20 i^g/ml and 50% inhibition was achieved only at 8 i^g/ml of the 
immunogen (Fig. 21). 
Purification and characterization of ROS modified glycated poly-L-lysine 
immune IgG 
Immunoglobulin G was isolated from pre-immune and immune rabbit 
antiserum of ROS-glycated poly-L-lysine by affinity chromatography on Protein A-
Sepharose colunm (Fig. 22). The purity of IgG was evaluated by SDS-polyacrylamide 
gel electrophoresis in the absence of a reducing agent. The purified IgG migrated as a 
single band on 7.5% gel (Fig. 22 inset). 
Direct binding ELISA of the purified ROS-glycated poly-L-lysine IgG showed 
strong reactivity towards its immunogen (Fig. 23). Pre-immune IgG from rabbit, as 
negative control, showed negligible binding. 
Band shift assay 
The binding of ROS-glycated poly-L-lysine with affinity purified anti-ROS-
glycated poly-L-lysine IgG was ascertained by band shift assay. Increasing the 
concentration of IgG, incubated with constant amount of antigen for 2 hr at 37°C and 
overnight at 4°C, resulted in a proportional increase in the formation of high 
molecular weight immune complexes as visualized by gradually increased band 
intensity near the wells in polyacrylamide gel electrophoresis (Fig. 24). 
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Fig. 20. Direct binding ELISA of ROS-glycated poly-L-iysine with preimmune 
(•) and immune (A) sera. Microtitre plates were coated with ROS-
glycated poly-L-lysine (10 |ig/ml). 
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Fig, 21. Inhibition ELISA of anti-ROS-glycated poly-L-lysine immune (•) and 
preimmune (•) sera with ROS-glycated poiy-L-lysine. Microtitre 
plates were coated with ROS-glycated poly-L-lysine (10 |ig/ml). 
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Fig. 22. Elution profile of anti-ROS-glycated poly-L-lysine IgG on Protein-A 
Sepharose affinity column. Inset: SDS-PAGE of purified IgG on 7.5% 
polyacrylamide gel. 
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Fig. 23. Binding of affinity purified anti-ROS-glycated poly-L-iysine immune 
IgG (A) and preimmune IgG (•) to ROS-glycated poly-L-lysine. 
Microtitre plates were coated with ROS-glycated poly-L-lysine (10 
^g/ml). 
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Fig. 24. Band shift assay of anti-ROS-glycated poly-L-lysine IgG binding to ROS-
glycated poly-L-lysine. Lane 1 contains anti-ROS-glycated poly-L-lysine 
IgG (10 \ig). Lanes 2-5 contain increasing concentration of IgG (10, 20, 30 
and 40 ^g) incubated for 2 hr at 37 °C and overnight at 4 °C with a constant 
amount of antigen (10 ^g). 
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Fig. 25. Inhibition ELISA of anti-glycated poly-L-lysine IgG binding to 
glycated poly-L-lysine. The inhibitors were native poly-L-lysine (o), 
glycated poly-L-lysine (•), ROS-glycated poly-L-lysine (A) and ROS 
poly-L-lysine (T). Microtitre plates were coated with glycated poly-L-
lysine (10 )ig/ml). 
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Fig. 26. Inhibition ELISA of anti-glycated poly-L-lysine IgG binding to 
glycated poly-L-lysine. The inhibitors were native human IgG (o), 
glycated human IgG (•) and ROS-glycated human IgG (A). Microtitre 
plates were coated with glycated poly-L-lysine (10 i^g/ml). 
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Fig. 27. Inhibition ELISA of anti-glycated poly-L-lysine IgG binding to glycated 
poly-L-lysine. The inhibitors were native HSA (o), glycated HSA (•) 
and ROS-glycated HSA (A). Microtitre plates were coated with 
glycated poly-L-lysine (10 (ig/ml). 
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Fig. 28. Inhibition ELISA of anti-glycated poly-L-lysine IgG binding to 
glycated poIy-L-lysine. The inhibitors were native histone (o), 
glycated histone (•) and ROS-glycated histone (A). Microtitre plates 
were coated with glycated poly-L-lysine (10 |ig/ml). 
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TABLE 7 
Antigenic specificity of anti-glycated poly-L-lysine antibodies 
Inhibitors Maximum % inhibition at 20 fig/ml 
Native poly-L-lysine 18.0 
ROS-poly-L-lysine 25.3 
Glycated poly-L-lysine 85.3 
ROS-glycated poly-L-lysine 29.0 
Native human IgG 20.1 
Glycated human IgG 55.0 
ROS-glycated human IgG 26.8 
Native HSA 18.6 
Glycated HSA 48.3 
ROS-glycated HSA 28.5 
Native Histone 16.3 
Glycated Histone 42.7 
ROS-glycated Histone 24.6 
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Fig. 29. Inliibition ELISA of anti-ROS-glycated poly-L-lysine IgG binding to 
ROS-glycated poly-L-lysine. The inhibitors were native poly-L-lysine 
(o), glycated poly-L-lysine (•), ROS-glycated poly-L-lysine (A) and 
ROS poly-L-lysine (T). Microtitre plates were coated with ROS-
glycated poly-L-lysine (10 ^ g/ml). 
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Fig. 30. Inhibition ELISA of anti-ROS-glycated poIy-L-lysine IgG binding to 
ROS-glycated poly-L-lysine. The inhibitors were native human IgG 
(o), glycated human IgG (•) and ROS-glycated human IgG (A). 
Microtitre plates were coated with ROS-glycated poly-L-lysine (10 
^g/ml). 
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Fig. 31. Inhibition ELISA of anti-ROS-glycated poly-L-lysine IgG binding to 
ROS-glycated poly-L-lysine. The inhibitors were native HSA (o), 
glycated HSA (•) and ROS-glycated HSA (A). Microtitre plates were 
coated with ROS-glycated poly-L-lysine (10 [xg/ml). 
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Fig. 32. Inhibition ELISA of anti-ROS-glycated poly-L-lysine IgG binding to 
ROS-glycated poly-L-lysine. The inhibitors were native histone (o), 
glycated histone (•) and ROS-glycated histone (A). Microtitre plates 
were coated with ROS-glycated poly-L-lysine (10 |J.g/ml). 
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TABLE 8 
Antigenic specificity of anti-ROS-glycated poly-L-lysine antibodies 
Inhibitors Maximum % inhibition at 20 (ig/ml 
Native poly-L-lysine 16.5 
ROS-poly-L-lysine 34.0 
Glycated poly-L-lysine 35.3 
ROS-glycated poly-L-lysine 82.6 
Native human IgG 19.8 
Glycated human IgG 25.2 
ROS-glycated human IgG 52.6 
Native HSA 16.1 
Glycated HSA 22.7 
ROS-glycated HSA 45.3 
Native Histone 18.0 
Glycated Histone 22.1 
ROS-glycated Histone 40.7 
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Antibodies against native and modified poly-L-lysine in the sera of diabetes 
patients 
Sera from diabetes patients were tested for binding to native and modified 
poIy-L-lysine (glycated poly-L-iysine and ROS-glycated poly-L-lysine) by direct 
binding and competitive ELISA. Thirty four serum samples of patients suffering from 
uncontrolled hyperglycemia (both types of diabetes mellitus) for long duration were 
used in the study. 
Serum antibodies from diabetes patients showed appreciable binding to 
modified forms of poly-L-lysine as compared to the native form (p<0.001). Similar 
results were obtained with the sera of diabetic patients having secondary 
complications (Fig. 33). However, glycated poly-L-lysine showed greater binding 
than ROS-glycated and NaBH4 reduced glycated forms of poly-L-lysine to serum 
antibodies in diabetes patients. The average absorbance at 410 nm with the sera of 
diabetes patients sera (without secondary complications) binding to native poly-L-
lysine, glycated poly-L-lysine, ROS-glycated poly-L-lysine and NaBH4 reduced 
glycated poly-L-lysine was 0.10±0.04, 0.63±0.07, 0.54±0.09 and 0.29±0.05 
respectively. The average observed absorbance with the sera of diabetes patients (with 
secondary complications) binding to native poly-L-lysine, glycated poly-L-lysine, 
ROS-glycated poly-L-lysine and NaBH4 reduced glycated poly-L-lysine was 
0.11±0.04, 0.72±0.08, 0.52±0.07 and 0.33±0.02 respectively. No appreciable binding 
was observed with the normal subjects. 
Competition ELISA of 22 diabetic patients' sera which showed strong binding 
to modified forms of poly-L-lysine was carried out to analyze the specific recognition 
of circulating autoantibodies in diabetic patients for native and modified poly-L-
lysine. The autoantibodies showed remarkably higher recognition for modified forms 
of poly-L-lysine than the native form (p<0.001) in all the sera tested. The maximum 
inhibition of serum antibodies by native, glycated, ROS-glycated and NaBH4 reduced 
glycated forms of poly-L-lysine was observed in the range of 13% to 20.8%, 42% to 
62.4%, 40.4% to 61% and 22.8% to 40.9% respectively (Figs. 34-55). The inhibition 
data of serum antibodies in diabetic patients has been summarized in Table 9. 
73 
0.8 
a 
O 
r^ 0.6 
u 
a 
S 0.4 
(0 
0.2 
Diabetic patients Diabetic patients 
(n = 34) with secondary 
complications 
(n = l l) 
Normal human 
subjects 
(n = 10) 
Types of Sera 
Fig. 33. Direct Binding of serum antibodies from diabetes patients to native poly-
L-lysine (•), glycated poly-L-lysine (•) and ROS-glycated poly-L-lysine 
(•) and NaBH4 reduced glycated poly-L-lysine ( ). Serum samples from 
normal human subjects served as control. The microtitre plates were 
coated with the respective antigens (10 ng/ml). 
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Fig. 33. Direct Binding of serum antibodies from diabetes patients to native poly-
L-Iysine (•), glycated poly-L-lysine (•) and ROS-glycated poly-L-lysine 
(•) and NaBH4 reduced glycated poly-L-lysine ( ). Serum samples from 
normal human subjects served as control. The microtitre plates were 
coated with the respective antigens (10 i^g/ml). 
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Fig. 34. Detection of autoantibodies against native and modified poly-L-lysine in 
the diabetes patients. Serum antibodies (sample 1) inhibition by native 
poly-L-lysine (o), glycated poly-L-lysine (•), ROS-glycated poly-L-
lysine (A) and NaBH4 reduced glycated poly-L-lysine (•). The 
microtitre plate was coated with glycated poly-L-lysine (10 i^ g/ml). 
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Fig. 35. Detection of autoantibodies against native and modified poly-L-lysine in 
the diabetes patients. Serum antibodies (sample 2) inhibition by native 
poiy-L-lysine (o), glycated poly-L-lysine (•), ROS-glycated poly-L-
lysine (A) and NaBH4 reduced glycated poly-L-lysine (•). The 
microtitre plate was coated with glycated poly-L-lysine (10 t^g/ml). 
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Fig. 36. Detection of autoantibodies against native and modified poly-L-lysine in 
the diabetes patients. Serum antibodies (sample 3) inhibition by native 
poly-L-lysine (o), glycated poIy-L-lysine (•), ROS-glycated poly-L-
lysine (A) and NaBH4 reduced glycated poly-L-lysine (•). The 
microtitre plate was coated with glycated poly-L-lysine (10 |ig/ml). 
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Fig. 37. Detection of autoantibodies against native and modified poly-L-lysine in 
the diabetes patients. Serum antibodies (sample 4) inhibition by native 
poIy-L-lysine (o), glycated poly-L-lysine (•), ROS-glycated poly-L-
lysine (A) and NaBH4 reduced glycated poly-L-lysine (•). The 
microtitre plate was coated with glycated poly-L-lysine (10 |ig/ml). 
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Fig. 38. Detection of autoantibodies against native and modified poIy-L-lysine in 
the diabetes patients. Serum antibodies (sample 5) inhibition by native 
poly-L-lysine (o), glycated poly-L-lysine (•), ROS-glycated poly-L-
lysine (A) and NaBH4 reduced glycated poly-L-lysine (•). The 
microtitre plate was coated with glycated poly-L-lysine (10 p-g/ml). 
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Fig. 39. Detection of autoantibodies against native and modified poiy-L-lysine in 
the diabetes patients. Serum antibodies (sample 6) inhibition by native 
poly-L-lysine (o), glycated poly-L-lysine (•), ROS-glycated poly-L-
lysine (A) and NaBH4 reduced glycated poly-L-lysine (•). The 
microtitre plate was coated with glycated poly-L-lysine (10 |ig/ml). 
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Fig. 40. Detection of autoantibodies against native and modified poly-L-lysine in 
the diabetes patients. Serum antibodies (sample 7) inhibition by native 
poly-L-lysine (o), glycated poly-L-lysine (•), ROS-glycated poly-L-
lysine (A) and NaBH4 reduced glycated poly-L-lysine (•). The 
microtitre plate was coated with glycated poly-L-lysine (10 pg/ml). 
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Fig. 41. Detection of autoantibodies against native and modified poly-L-lysine in 
the diabetes patients. Serum antibodies (sample 8) inhibition by native 
poly-L-lysine (o), glycated poly-L-lysine (•), ROS-glycated poly-L-
lysine (A) and NaBH4 reduced glycated poly-L-lysine (•). The 
microtitre plate was coated with glycated poly-L-lysine (10 |^g/ml). 
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Fig. 42. Detection of autoantibodies against native and modified poly-L-lysine in 
the diabetes patients. Serum antibodies (sample 9) inhibition by native 
poly-L-lysine (o), glycated poly-L-lysine (•), ROS-glycated poly-L-
lysine (A) and NaBH4 reduced glycated poly-L-lysine (•). The 
microtitre plate was coated with glycated poly-L-lysine (10 |ig/ml). 
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Fig. 43. Detection of autoantibodies against native and modified poly-L-lysine in 
the diabetes patients. Serum antibodies (sample 10) inhibition by native 
poly-L-lysine (o), glycated poly-L-lysine (•), ROS-glycated poly-L-
lysine (A) and NaBH4 reduced glycated poly-L-lysine (•). The 
microtitre plate was coated with glycated poly-L-lysine (10 |ig/ml). 
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Fig. 44. Detection of autoantibodies against native and modified poly-L-lysine in 
the diabetes patients. Serum antibodies (sample 11) inhibition by native 
poly-L-lysine (o), glycated poly-L-lysine (•), ROS-glycated poly-L-
lysine (A) and NaBH4 reduced glycated poly-L-lysine (•). The 
microtitre plate was coated with glycated poly-L-lysine (10 |J.g/ml). 
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Fig. 45. Detection of autoantibodies against native and modified poly-L-lysine in 
the diabetes patients. Serum antibodies (sample 12) inhibition by native 
poly-L-Iysine (o), glycated poly-L-lysine (•), ROS-glycated poIy-L-
lysine (A) and NaBH4 reduced glycated poly-L-lysine (•). The 
microtitre plate was coated with glycated poly-L-lysine (10 (ig/ml). 
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Fig. 46. Detection of autoantibodies against native and modified poly-L-lysine in 
the diabetes patients. Serum antibodies (sample 13) inhibition by native 
poly-L-lysine (o), glycated poly-L-lysine (•), ROS-glycated poly-L-
lysine (A) and NaBH4 reduced glycated poly-L-lysine (•). The 
microtitre plate was coated with glycated poly-L-lysine (10 (J-g/ml). 
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Fig. 47. Detection of autoantibodies against native and modified poly-L-lysine in 
the diabetes patients. Serum antibodies (sample 14) inhibition by native 
poly-L-lysine (o), glycated poly-L-lysine (•), ROS-glycated poly-L-
lysine (A) and NaBH4 reduced glycated poly-L-lysine (•). The 
microtitre plate was coated with glycated poly-L-lysine (10 (^g/ml). 
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Fig. 48. Detection of autoantibodies against native and modified poly-L-lysine in 
the diabetes patients. Serum antibodies (sample 15) inhibition by native 
poly-L-lysine (o), glycated poly-L-lysine (•), ROS-glycated poly-L-
lysine (A) and NaBH4 reduced glycated poly-L-lysine (•). The 
microtitre plate was coated with glycated poly-L-Iysine (10 ^g/ml). 
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Fig. 49. Detection of autoantibodies against native and modified poly-L-lysine in 
the diabetes patients. Serum antibodies (sample 16) inhibition by native 
poly-L-lysine (o), glycated poly-L-lysine (•), ROS-glycated poly-L-
lysine (A) and NaBH4 reduced glycated poly-L-lysine (•). The 
microtitre plate was coated with glycated poly-L-lysine (10 |ig/ml). 
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Fig. 50. Detection of autoantibodies against native and modified poly-L-lysine in 
the diabetes patients. Serum antibodies (sample 17) inhibition by native 
poly-L-lysine (o), glycated poly-L-lysine (•), ROS-glycated poly-L-
lysine (A) and NaBH4 reduced glycated poly-L-lysine (•). The 
microtitre plate was coated with glycated poly-L-lysine (10 |ig/ml). 
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Fig. 51. Detection of autoantibodies against native and modified poly-L-lysine in 
the diabetes patients. Serum antibodies (sample 18) inhibition by native 
poIy-L-lysine (o), glycated poly-L-lysine (•), ROS-glycated poly-L-
lysine (A) and NaBH4 reduced glycated poly-L-lysine (•). The 
microtitre plate was coated with glycated poly-L-lysine (10 (^g/ml). 
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Fig. 52. Detection of autoantibodies against native and modified poly-L-lysine in 
the diabetes patients. Serum antibodies (sample 19) inhibition by native 
poly-L-lysine (o), glycated poly-L-lysine (•), ROS-glycated poly-L-
lysine (A) and NaBH4 reduced glycated poly-L-lysine (•). The 
microtitre plate was coated with glycated poly-L-lysine (10 |ig/ml). 
93 
c 
20-
I 40 
c 
o 
o 
L . 
o 
Q. 
60-
80-
100 
0.01 
1 1 1 1 1 1 — 
0.1 
- I—I—I I r I 11 
1 
- I — I I I I I 1 1 — 
10 
-l—I I I I I I 
100 
Inhibitor Concentration, [iglm\ 
Fig. 53. Detection of autoantibodies against native and modified poly-L-lysine in 
the diabetes patients. Serum antibodies (sample 20) inhibition by native 
poly-L-lysine (o), glycated poly-L-lysine (•), ROS-glycated poly-L-
lysine (A) and NaBH4 reduced glycated poly-L-lysine (•). The 
microtitre plate was coated with glycated poly-L-lysine (10 |ig/ml). 
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Fig. 54. Detection of autoantibodies against native and modified poly-L-lysine in 
the diabetes patients. Serum antibodies (sample 21) inhibition by native 
poly-L-lysine (o), glycated poly-L-lysine (•), ROS-glycated poly-L-
lysine (A) and NaBH4 reduced glycated poly-L-lysine (•). The 
microtitre plate was coated with glycated poly-L-lysine (10 |ig/ml). 
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Fig. 55. Detection of autoantibodies against native and modified poly-L-lysine in 
the diabetes patients. Serum antibodies (sample 22) inhibition by native 
poly-L-lysine (o), glycated poly-L-lysine (•), ROS-glycated poly-L-
lysine (A) and NaBH4 reduced glycated poly-L-lysine (•). The 
microtitre plate was coated with glycated poly-L-lysine (10 fig/ml). 
96 
TABLE 9 
Antibodies against native poIy-L-lysine and modified forms of poly-L-lysine in 
the sera of diabetes patients 
Sera No. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
Mean ~-z SD 
Maximum % inhibition at 20 fig/ml 
Native 
poIy-L-Iysine 
16.6 
20.8 
18.2 
13.0 
17.3 
16.0 
18.0 
16.0 
19.0 
15.1 
18.2 
14.0 
13.7 
15.3 
18.0 
17.4 
19.0 
15.6 
16.4 
14.0 
18.5 
14.8 
16.5 ±1.9 
Glycated 
poly-L-lysine 
53.8 
56.0 
42.0 
60.8 
52.0 
57.8 
59.3 
52.0 
55.7 
48.3 
61.3 
45.6 
51.0 
53.4 
50.8 
56.0 
59.0 
57.2 
56.2 
57.0 
62.0 
58.6 
54.8 ±5.1 
ROS-glycated 
poly-L-lysine 
60.0 
48.5 
43.0 
40.4 
49.5 
56.0 
47.0 
51.6 
54.0 
42.7 
51.0 
46.0 
58.0 
55.1 
54.3 
56.5 
53.0 
61.0 
45.0 
52.0 
56.4 
53.8 
51.6±5.7 
NaBH4 reduced 
glycated 
poly-L-lysine 
29.0 
28.2 
24.6 
40.9 
28.6 
36.0 
37.6 
26.2 
34.0 
25.0 
38.4 
22.8 
30.2 
32.6 
28.3 
31.3 
35.6 
34.6 
33.8 
35.0 
40.4 
36.0 
32.2 ±5.1 
Statistical data shows significant binding of modified forms of poly-L-lysine than 
native poly-L-lysine (p<0.001) with antibodies in the diabetes sera. 
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In the case of diabetic patients having secondary complications, the observed 
inhibition at 20 |ig/ml, with native, glycated, ROS-glycated and NaBH4 reduced 
glycated forms of poly-L-lysine was in the range of 12.8% to 18.5%, 55% to 68%, 
51% to 63% and 30.4% to 49.2% respectively (Figs. 56-66). The data (Table 10) 
reveal significant inhibition of antibodies by the modified forms of poly-L-lysine as 
compared to native poly-L-lysine (p<0.001). 
Purification of diabetic patients IgG 
Sera 3, 7 and 9 of diabetes patients with secondary complications showing 
maximum recognition of modified forms of poly-L-Iysine, were used for the 
purificalion of IgG. IgG was also isolated from normal human subject. IgG purified 
by affinity chromatography on Protein A-Sepharose column eluted as a symmetrical 
single peak (Fig. 67). Purified IgG migrated as a single homogenous band on SDS-
PAGE under non-reducing conditions (Fig. 67 inset). 
Anti-glycated poly-L-lysine and anti-ROS-glycated poly-L-lysine antibodies 
binding to IgG from diabetes patients 
Diabetes induced glycation in the IgG isolated from various diabetic patients 
was probed by our experimentally induced antibodies against Amadori-rich glycated 
poly-L-lysine. Immune complexes were formed between the IgGs purified from the 
sera of diabetes patients and the induced anti-glycated poly-L-lysine antibodies. The 
immune complexes thus formed were used in competition inhibition ELISA on the 
plates coated with glycated poly-L-lysine. The induced anti-glycated poly-L-lysine 
antibodies were inhibited to the extent of 46 to 55.6 percent at a maximum 
concentration of 20 (ig/ml of the IgG from the diabetes pafients (Fig. 68). 
However, when immune complexes were formed between the IgGs isolated 
from the diabetes patients and experimentally induced anti-ROS-glycated poly-L-
lysine antibodies, the observed inhibition in the activity of our induced antibodies 
ranged from 42 to 51 percent in the competitive binding assay on a plate coaled \^ 'ilh 
ROS-glycated poly-L-lysine (Fig. 69). 
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Fig. 56. Detection of autoantibodies against native and modified poly-L-iysine in 
the diabetes patients having secondary complications (DC). DC serum 1 
inhibition by native poly-L-lysine (o), glycated poly-L-lysine (•), ROS-
glycated poly-L-Iysine (A) and NaBH4 reduced glycated poly-L-lysine 
(•). The microtitre plate was coated with glycated poly-L-lysine (10 
^g/ml). 
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Fig. 57. Detection of autoantibodies against native and modified poly-L-lysine in 
the diabetes patients having secondary complications (DC). DC serum 2 
inhibition by native poly-L-lysine (o), glycated poly-L-lysine (•), ROS-
glycated poly-L-lysine (A) and NaBH4 reduced glycated poly-L-lysine 
(•). The microtitre plate was coated with glycated poly-L-lysine (10 
lig/ml). 
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Fig. 58. Detection of autoantibodies against native and modified poly-L-lysine in 
the diabetes patients having secondary complications (DC). DC serum 3 
inhibition by native poly-L-lysine (o), glycated poly-L-lysine (•), ROS-
glycated poly-L-lysine (A) and NaBH4 reduced glycated poly-L-lysine 
(•). The microtitre plate was coated with glycated poly-L-lysine (10 
^g/ml). 
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Fig. 59. Detection of autoantibodies against native and modified poly-L-lysine in 
the diabetes patients having secondary comphcations (DC). DC serum 4 
inhibition by native poly-L-lysine (o), glycated poly-L-lysine (•), ROS-
glycated poly-L-lysine (A) and NaBH4 reduced glycated poly-L-lysine 
(•). The microtitre plate was coated with glycated poly-L-lysine (10 
|ig/ml). 
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Fig. 60. Detection of autoantibodies against native and modified poly-L-Iysine in 
the diabetes patients having secondary complications (DC). DC serum 5 
inhibition by native poly-L-lysine (o), glycated poly-L-lysine (•), ROS-
glycated poly-L-lysine (A) and NaBH4 reduced glycated poly-L-lysine 
(•). The microtitre plate was coated with glycated poly-L-lysine (10 
|ig/ml). 
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Fig. 61. Detection of autoantibodies against native and modified poly-L-lysine in 
the diabetes patients having secondary complications (DC). DC serum 6 
inhibition by native poly-L-lysine (o), glycated poly-L-lysine (•), ROS-
glycated poly-L-lysine (A) and NaBH4 reduced glycated poly-L-lysine 
(•). The microtitre plate was coated with glycated poly-L-lysine (10 
|ig/ml). 
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Fig. 62. Detection of autoantibodies against native and modified poly-L-lysine in 
the diabetes patients having secondary complications (DC). DC serum 7 
inhibition by native poly-L-lysine (o), glycated poly-L-lysine (•), ROS-
glycated poly-L-lysine (A) and NaBH4 reduced glycated poly-L-lysine 
(•). The microtitre plate was coated with glycated poly-L-lysine (10 
jig/ml). 
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Fig. 63. Detection of autoantibodies against native and modified poly-L-lysine in 
the diabetes patients having secondary compHcations (DC). DC serum 8 
inhibition by native poly-L-lysine (o), glycated poly-L-lysine (•), ROS-
glycated poly-L-lysine (A) and NaBH4 reduced glycated poly-L-lysine 
(•). The microtitre plate was coated with glycated poly-L-lysine (10 
l^g/ml). 
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Fig, 64. Detection of autoantibodies against native and modified poly-L-lysine in 
the diabetes patients having secondary complications (DC). DC serum 9 
inhibition by native poly-L-iysine (o), glycated poly-L-lysine (•), ROS-
glycated poly-L-lysine (A) and NaBH4 reduced glycated poly-L-lysine 
(•). The microtitre plate was coated with glycated poly-L-lysine (10 
\ig/m\). 
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Fig. 65. Detection of autoantibodies against native and modified poly-L-lysine in 
the diabetes patients having secondary complications (DC). DC serum 
10 inhibition by native poly-L-lysine (o), glycated poly-L-lysine (•), 
ROS-glycated poly-L-lysine (A) and NaBH4 reduced glycated poly-L-
lysine (•). The microtitre plate was coated with glycated poly-L-lysine 
(lO^g/ml). 
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Fig. 66. Detection of autoantibodies against native and modified poly-L-lysine in 
the diabetes patients having secondary compHcations (DC). DC serum 
11 inhibition by native poly-L-lysine (o), glycated poly-L-lysine (•), 
ROS-glycated poly-L-lysine (A) and NaBH4 reduced glycated poly-L-
lysine (•). The microtitre plate was coated with glycated poly-L-lysine 
(10 ^g/ml). 
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TABLE 10 
Antibodies against native poly-L-iysine and modified forms of poly-L-lysine in 
the sera of diabetes patients having secondary complications 
Sera No. 
Diabetic 
Nephropathy 
] 
0 
3 
4 
Diabetic 
Retinopathy 
5 
() 
8 
Diabetic 
Atherosclerosis 
9 
10 
11 
Mean--rSD 
Maximum % inhibition at 20 ^g/ml 
Native 
poly-L-Iysine 
14.3 
12.8 
17.6 
15.6 
18.0 
18.5 
16.0 
15.3 
16.8 
18.2 
14.0 
16.1 ±1.8 
Glycated 
poIy-L-Iysine 
67.4 
65.0 
68.2 
63.7 
62.1 
56.0 
67.2 
54.0 
65.0 
58.0 
61.0 
62.5 ±4.8 
ROS-glycated 
poIy-L-Iysine 
63.0 
58.6 
61.0 
54.2 
53.4 
54.0 
60.8 
56.0 
61.0 
52.0 
59.0 
57.5 ±3.7 
NaBH4 reduced 
glycated 
poly-L-lysine 
48.3 
42.0 
49.2 
46.3 
41.6 
31.2 
44.9 
30.4 
44.5 
38.4 
39.8 
41.5 ±6.2 
Statistical data shows significant binding of modified forms of poly-L-lysine than 
native poly-L-lysine (p<0.001) with antibodies in diabetic sera with secondary 
complications. 
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Fig. 67. Elution profile of an isolated IgG from diabetes patients with secondary 
complications on protein-A Sepharose affinity column. Inset: SDS-PAGE 
of purified IgG on 7.5% polyacrylamide gel. 
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Fig. 68. Inhibition of anti-giycated poly-L-iysine IgG binding to glycated poly-L-
lysine by IgG isolated from sera of normal healthy subject (o) and 3 
diabetes patients with secondary complications (•, A, • ) . The microtitre 
plate was coated with glycated poly-L-lysine (10 |ig/ml). 
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Fig. 69. Inhibition of anti-ROS-glycated poly-L-lysine IgG binding to ROS-
glycated poly-L-iysine by IgG isolated from sera of normal healthy 
subject (o) and 3 diabetes patients with secondary complications (•, A, 
•) . The microtitre plate was coated with ROS-glycated poIy-L-lysine (10 
[ig/ml). 
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For control experimentation IgG isolated from normal human subject 
produced only 15 to 18 percent inhibition in the activities of anti-glycated poly-L-
lysine and anti-ROS-glycated poly-L-lysine antibodies. 
The percent inhibition data of the IgGs isolated from the diabetes patients and 
normal human subject with anti-glycated poly-L-lysine and anti-ROS-glycated poly-
L-lysine antibodies has been presented in Table 11. 
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TABLE 11 
Binding of anti-glycated poly-L-Iysine and anti-ROS-glycated poly-L-Iysine 
antibodies to IgG from the sera of normal subject and diabetes patients 
Maximum % inhibition at 20 fig/ml 
Serum Glycated poly-L-lysine ROS-glycated poly-L-lysine 
Isolated IgG 
Diabetes patients with 
secondary complications 
1 55.6 51.0 
2 48.3 46.7 
3 46.0 42.0 
Normal healthy subject 18.0 16.8 
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Discussion 
Hyperglycemia plays an important role in the pathogenesis of diabetic 
complications by increasing protein glycation with the gradual build up of advanced 
glycation end-products (AGEs) in body tissues. Protein glycation and the formation of 
AGEs are accompanied by increased free radical activity by mitochondria that 
contribute toward the biomolecular damage in diabetes (Ahmed, 2005). AGE 
formation is an inevitable process in vivo and can be accelerated under pathological 
conditions such as oxidative stress. The increase in glycoxidation products in plasma 
and tissue proteins suggests that oxidative stress is increased in diabetes (Baynes and 
Thorpe, 1999; Ahmed et al, 2005). The majority of the glycated proteins in plasma of 
diabetic patients exist as Amadori products rather than in the more labile Schiff base 
form (Cuniss and Witztum, 1983; Cohen and Ziyadeh, 1994) and only a small part of 
the Amadori products undergo subsequent rearrangements to AGEs. Among AGE-
structures, N'^ -carboxymethyllysine (CML) formation by oxidative cleavage of 
Amadori adducts represent a major pathway in vivo (Ahmed et al, 1986; Smith and 
Thomalley, 1992; Wells-Knecht et al, 1995). -OH generated by Fenton reaction 
between Fe and Amadori product-derived endogenous H2O2 plays an important role 
in oxidative cleavage of Amadori compounds into CML (Nagai et al. 1997). These 
modifications on protein may lead to the formation of neoantigens which could in turn 
initiate autoimmunity. 
Since amino groups of lysine residues are major sites for glycation of proteins, 
poly-L-lj'sine was chosen as a model compound for this study. It was modified with 
glucose and the resultant glycated poly-L-lysine was further modified with -OH 
generated through Fenton reaction. High degree of Amadori product formation in the 
glycated poly-L-lysine was detected by NBT assay, which is specific for Amadori 
products but not for AGEs (Johnson et al, 1982; Lapolla et al, 2005). Our results 
showed higher yield of Amadori products in glycated poly-L-lysine than ROS-
glycated poly-L-lysine. The yield got further increased when glycation was carried 
out in the presence of DTPA, a metal ion chelator which is known to inhibit 
glycoxidation and cross linking (Graf e/ al, 1984 and 1987). The chelator is also 
known to inhibit the development of AGE-specific fluorescence in proteins without 
significantly affecting the glycation of proteins (Fu etal, 1994). 
The thiobarbituric acid (TEA) assay for glycated proteins has been used for 
providing structural evidence of hexose bound to hemoglobin (Ney et al, 1981). The 
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higher yield of HMF in glycated poly-L-lysine than in ROS-glycated poIy-L-lysine is 
in agreement with the earlier finding (Tsuchiya et al, 1984). 
The far-UV spectrum of poly-L-Iysine exhibited a peak at 202 nm 
representing a randomly coiled form. This is in accordance with an earlier study 
(Rosenheck and Doty, 1961). However, hyperchromicity was observed in the case of 
glycated poly-L-lysine and ROS-glycated poly-L-lysine which could be due to 
structural perturbation in poly-L-lysine as a result of unfolding and aggregation of 
molecules upon glycation and -OH mediated oxidation. Glycation induced protein 
unfolding leading to aggregation has earlier been reported (Perry et al, 1987; 
Bucciantini et al, 2002). 
ROS modification of glycated poly-L-lysine in the presence of various metal 
ion chelators and antioxidants was undertaken to ascertain the particular reactive 
oxygen species involved in the reaction. The reaction was significantly inhibited by 
EDTA, catalase and mannitol, whereas the effect of SOD was quite insignificant. This 
confirms the involvement of 'OH radical in Fe^ "^ and H2O2 mediated ROS modification 
of Amadori poly-L-lysine. The slightly lower inhibition by mannitol, as compared to 
catalase could be explained by the possibility that hydroxyl radical generated by 
Fenton reaction near metal-binding sites of glycated proteins can react readily with 
2.3-dicarbonyl compound before they are quenched (Chevion, 1988; Chace et al, 
\99\;K:Aio etal, 1992). 
The presence of multiple excitation and emission bands in fluorescence 
spectra of poly-L-lysine is in line with an earlier study (Homchaudhuri and 
Swaminathan, 2001) on concentrated solutions of lysine, indicating the involvement 
of multiple states and/or multiple species. Since poly-L-lysine lacks any aromatic 
residue that can contribute to fluorescence, the origin of the observed fluorescence 
can be attributed to intramolecular interactions between side chains of lysine residues 
in solution (Homchaudhuri and Swaminathan, 2001 and 2004). The excitation 
wavelength of poly-L-lysine at 290 nm has been used to evaluate the changes in the 
fluorescence intensity of modified poly-L-lysine at the emission wavelength of 325 
nm. The decrease in fluorescence intensity in the modified poly-L-lysine could be 
attributed to modification of free amino groups in lysine side chains. The increase in 
emission intensity of ROS-glycated poly-L-lysine at 365 nm could be due to 
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fragmentation of the polypeptide, as a result of ROS exposure and also due to 
availability of lysine-lysine pairs as a result of oxidation of glycated poly-L-lysine. 
It is apparent from the far-UV c.d. spectra that poly-L-lysine exists in random 
coil structure at pH 7.4 in the described conditions while modified poly-L-lysine 
showed significant changes in ellipticities at 217 nm and 200 nm. The decrease in 
ellipticity of modified poly-L-lysine at 217 nm was due to alteration of mean residue 
weight of poly-L-lysine on glycation as supported by earlier study of far U.V. c.d. on 
glycated poIy-L-lysine (Liang, 1990). The increase in ellipticity of modified poly-L-
lysine at 200 nm could be due to alteration in the original conformation of poly-L-
lysine on glycation and -OH mediated oxidation of glycated poly-L-lysine. 
Results on FT-IR spectra clearly showed the position and intensity of 
characteristic bands in poly-L-lysine and modified poly-L-lysine. The shifting and 
increase in intensity of the amide 1 bands in modified poly-L-lysine indicate a change 
in the peptide group state (Rozenberg and Shoham, 2007) as a result of glycation and 
oxidation of reactive amino groups in glycated poly-L-lysine and ROS-glycated poly-
L-lysine respectively. The C-N group specific band in the spectra of glycated poly-L-
lysine and ROS-glycated poly-L-lysine could be due to exposure of these buried 
groups on denaturation-cum-unfolding of poly-L-lysine after the modifications. The 
appearance of band at 1702 cm'', corresponding to carbonyl (C==0) group of ketones 
in the spectra of glycated poly-L-lysine, confirmed the formation of ketoamines 
(Amadori product) in the glycated poly-L-lysine (Wnorowsky and Yaylayan, 2003; 
Yaylayan and Locas 2007). The presence of more prominent and intense band of 
methylene (CH2) group in ROS-glycated poly-L-lysine spectrum is reported for 
carboxymethylated arginine or lysine (Cardenas et al, 2004). Carboxymethylation of 
lysine is known to generate CML, an advanced glycation end product. The shifting 
and increase in band intensity of e-NH2 groups in glycated poly-L-lysine and ROS-
glycated poly-L-lysine could be due to attachment of glucose moiety during glycation 
and further modification during oxidation of side chain e-amino groups respectively. 
These results are in conformity with the earlier investigations that absorption of poly-
L-lysine due to side chain NH2 groups, extensively studied in multiple peptide model 
systems, is generally found at 3400-3100 cm"' (Susi, 1969; Rozenberg el al, 2005). 
In the ' H - N M R spectrum of poly-L-lysine the different chemical shifts of e-
methylene (e-CH2) protons and other protons indicate the presence of different lysine 
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residues in poly-L-lysine. This difference is due to distinct pK values of the lysine 
residues (Tressi et al, 2002). The NMR analysis clearly shows the glycation in 
modified poly-L-lysine. This was confirmed by the e-methylene protons chemical 
shift differences between the modified and unmodified counterparts of poly-L-lysine 
and presence of the proton signals of glucose (Gruetter^^r al, 1996) in glycated poly-
L-lysine. The appearance of singlet resonance signal of methylene proton of glucose 
in the spectra of ROS-glycated poly-L-lysine has been reported in the spectrum of 
CML (Delatour et al., 2006). 
The antigenicity of native and modified poly-L-lysine was ascertained by 
experimental induction of antibodies in rabbits. Both the modified forms of poly-L-
lysine were found to be extremely potent antigens inducing high titre antibodies in the 
animals. However, immunization with native poly-L-lysine could result only in a 
weak antigenic response. The antibody titre was checked through direct binding solid-
phase immunoassay. The non-antigenicity of poly-L-lysine may be due to its 
homopolymeric nature and lack of aromatic residue (Rao, 1972; Goldsby et al., 2003). 
However glycation as well as ROS modification of glycated poly-L-lysine results in 
structural changes/conformational alteration thus imparting a highly antigenic 
characteristic to the poly-L-Iysine. Amadori products of HSA and proteins containing 
AGEs have been reported to be highly immunogenic in experimental animals with 
CML as one of the major epitopes recognized by anti-AGE antibodies (Reddy et al., 
1995; Ikedaetal., 1996; Schalkwijk^/^/., 1999). 
The antigenic specificity of affinity purified anti-glycated poly-L-lysine IgG 
and anti-ROS-glycated poly-L-lysine IgG was ascertained by competition ELISA and 
band shift assay. The results reiterate that the induced antibodies are iramunogen 
specific and recognizing the modified epitopes on poly-L-lysine. The in vivo 
generation of autoantibodies can be explained as a result of hyperglycemia wherein 
glucose and reactive oxygen species may induce modifications in certain proteins 
generating neoepitopes against which the antibodies are raised. Autoantibodies 
directed against intracellular proteins have been found to be serological markers of 
diabetes disease (Makino et al., 1995). 
The induced antibodies showed appreciable recognition for glycated IgG, 
HSA and histone. These molecules caused an inhibition of 42.7% to 55% in the 
activity of experimentally induced anti-glycated poly-L-lysine antibodies. These 
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results ckjarly point towards epitope sharing between the glycated poly-L-lysine and 
glucose modified IgG, HSA and histone. While anti-ROS-glycated poly-L-lysine 
antibodies inhibited in the range of 34% to 52.6% by ROS-glycated counterparts of 
IgG, RSA, histone and ROS-poly-L-lysine. However native counterparts of the above 
mentioned proteins did not cause appreciable inhibition in the activities of anti-
modified poly-L-lysine antibodies. The induced antibodies against the modified forms 
of poly-L-lysine are found to be polyspecific and cross reactive with a variety of 
inhibitors having common antigenic determinants. These results explain that one of 
the factors for the in vivo induction of antibodies in diabetes mellitus is 
hyperglycemia induced glycation of certain proteins as well as their oxidative 
modification by the reactive oxygen species generated under stress. 
Amadori products have been found in the fissues of diabetic rats as well as in 
diabetic patients (Myint et al, 1995; Schalkwijk et al, 1999; Jaleel et al, 2005). 
AGEs are also reported to be accumulated in the tissues of diabetic patients (Kume et 
al, 2005). The presence of anti-CML-BSA antibodies has been reported in the serum 
of streptozotocin-diabetic rats as well as in a small number of diabetic patients 
(Shibayama et al, 1999). In the present study, we have invesfigated the possible role 
of native and modified (glycated, ROS-glycated and NaBH4 reduced glycated) forms 
of poly-L-lysine in diabetes mellitus. Serum antibodies from diabetic patients, when 
analyzed in competitive binding assay, showed highest recognition of glycated poly-
L-lysine Maximum inhibition in the antibody activity was caused by Amadori-rich 
glycated poly-L-lysine, followed by ROS-glycated poly-L-lysine or NaBH4 reduced 
glycated poly-L-lysine and least with the native poly-L-lysine. Thus circulafing 
autoantibodies in the sera of diabetic patients showed preferential recognition of the 
epitopes on modified poly-L-lysine as compared to the native forai. 
The presence of autoantibodies against native and modified forms of poly-L-
lysine in the sera of diabetic patients having secondary complications (nephropathy, 
retinopathy and atherosclerosis) was also investigated. Earlier studies have shown the 
presence of autoantibodies directed against AGEs in diabetic patients having 
secondary complications (Rahbar and Figarola, 2003). Higher autoantibodies against 
AGEs have been reported in patients with the renal failure than in nomial subjects or 
diabetic subjects without renal failure (Shibayama et al, 1999). Amadori products of 
glycated serum proteins and Amadori albumin have been reported to be associated 
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with glomeruli of diabetic patients having nephropathy (Cohen and Ziyadeh, 1994; 
Sakai et ah, 1996). Elevated concentrations of Amadori albumin in animals have been 
implicated in the development of diabetic retinopathy (Clements et al, 1998). In our 
studies maximum recognition of Amadori-rich glycated poly-L-lysine followed by 
ROS-glycated poIy-L-lysine and NaBH4 reduced glycated poly-L-lysine was observed 
in the sera of diabetic patients with nephropathy. Similarly high recognition of 
Amadori-rich glycated poly-L-lysine was observed in the sera of diabetic patients 
with retinopathy and atherosclerosis. Recognition of native poly-L-lysine was the 
least. 
In vitro glycated albumin (Amadori adducts) has been shovm to stimulate 
tumor necrosis factor-a gene expression and modulate nitric oxide synthase activity in 
endothelial cells (Amore et al, 1997) and is associated with other activities (Cohen 
and Ziyadeh, 1994) in glomerular mesangial cells that are possibly involved in the 
pathogenesis of nephropathy. Interaction of Amadori albumin with specific receptors 
that can induce receptor-mediated responses (Predescu et al, 1988) and accumulation 
of immunocomplexes of AGEs and their autoantibodies in glomeruli might contribute 
to the diabetic pathogenesis (Shibayama et al, 1999). 
The straight chain of the Amadori adduct, ketoamine, undergoes cyclization to 
a more stabilized hemiketal furanose or pyranose ring structures (Armbruster, 1987; 
Yaylayan and Huyghues-Despointes, 1994). NaBH4 is effective in the reduction of 
Amadori products, but not of AGEs. In this study reduced form of glycated poly-L-
lysine showed impaired recognitions of the induced anti-glycated poIy-L-lysine 
antibodies as well as of the autoantibodies from diabetic patients sera due to change in 
the structure of Amadori products as a result of reduction by NaBH4 leading to 
elimination of keto group of the ketoamine. This results in shifting the existing 
equilibrium between the linear configuration and the furanose or pyranose ring 
structures more towards the linear configuration (Schalkwijk et al, 1999). The results 
suggest that the ring structures responsible for the antigenic epitope of Amadori-rich 
glycated poly-L-lysine are essential for recognition of the molecule by the antibodies. 
IgG has greater number of lysine residues than other serum proteins like 
albumin and red blood cells and hyperglycemia and/or oxidative stress can cause 
AGE-damaged IgG. Advanced glycation of IgG and other immunoglobulins has been 
shown 10 occur in serum of diabetic patients (Kaneshige, 1987; Kalia et al, 2004). 
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Recognition of the IgG from diabetes patients by our induced anti-glycated- and anti-
ROS-glycated-poly-L-lysine antibodies clearly shows the presence of glycated and 
ROS modified epitopes on the IgG from diabetes patients. However, presence of 
glycated as well as ROS modified epitopes on the diabetes IgG is further corroborated 
by the r(xognition of in vitro glycated normal human IgG by our experimentally 
induced antibodies against glycated- and ROS-glycated-poly-L-lysine. On the other 
hand the native (i.e. unglycated IgG) from the healthy human subject was poorly 
recognized by the induced antibodies. 
Based on the above studies the following conclusions can be drawn: 
1. The glycated poly-L-lysine, formed upon incubation of poly-L-lysine with 
glucose, was found to contain high concentration of early glycation (Amadori) 
products. 
2. Hydroxyl radical modification of the glycated poIy-L-lysine was achieved by 
'OH radical generated in the Fenton reaction. 
3. The modifications cause major biochemical and biophysical changes in poly-
L-lysine resulting in hyperchromicity and decreased fluorescence intensity in 
the spectral analysis. 
4. Both the glycated and ROS-glycated poly-L-lysine were found to be highly 
immunogenic in experimental animals despite the native form of poly-L-lysine 
being non-antigenic. 
5. Induced antibodies against modified poly-L-lysine forms were highly specific 
for the respective antigens. However, they also showed cross reactivity with 
glycated and ROS-glycated forms of certain lysine rich proteins. 
6. Less recognition of NaBH4 reduced glycated poly-L-lysine by the induced 
anti-glycated poly-L-lysine antibodies clearly show that the induced antibodies 
are predominantly formed against the Amadori components of glycated poly-
L-lysine. 
7. Autoantibodies from diabetic patients, with or without secondary 
complications, showed higher recognition for Amadori-rich glycated- and 
ROS-glycated-poly-L-lysine than the unmodified form. The antibodies from 
122 
normal healthy subjects showed negligible binding to either forms of poly-L-
lysine as well as to the native form. 
8. Higher recognition of autoantibodies in the diabetes patients by Amadori-rich 
glycated poly-L-lysine as compared to the ROS modified glycated poly-L-
lysine or the NaBH4 reduced glycated poly-L-lysine provides ample evidence 
that the major population of autoantibodies in diabetes patients is directed 
a]?ainst the intact (unmodified/analtered) Amadori components of the glycated 
poly-L-lysine. 
9. Furanose or pyranose (cyclic) forms of Amadori product are the potential 
epitopes responsible for higher recognition of glycated poIy-L-Iysine. 
10. Recognition of IgG from diabetes patients by anti-glycated- and anti-ROS-
glycated-poly-L-lysine antibodies points towards the presence of glycation and 
ROS induced damage in diabetes IgG. 
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